Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV

Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12637 total CTIS records — a stated recency window, not the full historical archive. Synced 16 Oct 2026, 03:17 UTC

2557

Shown in this register

most recently authorised

12,637

Total on CTIS

full historical archive

779

Phase III

within the shown window

Top member states

Spain 1071 France 924 Germany 907 Italy 776 Poland 609 Netherlands 560

Narrow the registerReset

Search within results

Phase

Lead sponsor

Member state

All 28 states

Trials with a site in France

Phase

Study

Lead sponsor

Area

Member states

Decision

Phase I

A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination with Other Agents, in Patients with Myeloid Malignancies

2026-526963-39-00Myeloid Malignancies

BeOne Medicines I GmbH

Neoplasms

France

15/10/2026

Phase I

A Study of ARC-02 in B-cell NHL

2026-525606-35-00B-cell Non Hodgkins Lymphoma (NHL)

Taiho Oncology Inc.

Neoplasms

France, Italy

13/10/2026

Phase III

A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

2026-525757-37-00Metabolic dysfunction-associated steatohepatitis

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Netherlands, Germany, France, Italy, Bulgaria, Belgium, Greece

13/10/2026

Phase II

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment with Efimosfermin Alfa in Adult Participants with Alcohol-related Liver Disease (ALD)

2026-526391-23-00Liver Diseases, Alcoholic

Glaxosmithkline Research & Development Limited

Digestive System Diseases

Spain, Denmark, Italy, France, Germany, Greece

12/10/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Huntington’s disease (HD).

2026-526093-16-00Huntington’s disease (HD).

DrugPridopidine

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Spain, Italy, Portugal, France, Netherlands, Germany, Belgium, Czechia

12/10/2026

Phase III

A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)

2026-525755-82-00Metabolic dysfunction-associated steatohepatitis

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Netherlands, Greece, Spain, Italy, France, Belgium, Germany

12/10/2026

Phase III

A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)

2025-524079-22-00KRAS G12D-mutated Locally Advanced (Unresectable) or Metast…

DrugSetidegrasib

Astellas Pharma Global Development Inc.

Neoplasms

Italy, Poland, Spain, France, Belgium, Germany

12/10/2026

Phase II

MOST-Express – A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients.

2025-522058-38-00HER2-positive rare cancer, HER2 positive non-small cell lun…

DrugTrastuzumab deruxtecan

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

09/10/2026

Phase II

CombiMucor - Efficacy of combination therapy with isavuconazole and intermittent high doses liposomal amphotericin B for the treatment of mucormycosis

2025-521505-40-00Adults with mucormycosis

DrugAmphotericin B

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

09/10/2026

Phase III

COTRIM-HIGH - Efficacy of daily prophylaxis with Cotrimoxazole 800/160mg on the occurrence of bacterial infections at six months after renal transplantation

2026-526183-20-00bacterial infection, kidney transplant

DrugTrimethoprim-sulfamethoxazole

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

08/10/2026

Phase I

First-in-Human Trial of DS1025a in Participants with Advanced Solid Tumors

2026-525284-41-00Advanced Solid Tumors Metastatic Solid Tumor Unresectable …

Daiichi Sankyo Inc.

Neoplasms

France

08/10/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)

2025-525114-38-00Pulmonary Arterial Hypertension (PAH)

Ns Pharma Inc.

Respiratory Tract Diseases

France, Germany, Poland, Italy, Belgium, Spain, Greece

08/10/2026

Phase III

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants with Obesity or Overweight With at Least One Weight Related Comorbidity Without Type 2 Diabetes Mellitus

2025-523379-41-00Obesity or Overweight, Weight-Related Comorbidity, without …

DrugLenbelintide

AstraZeneca AB

Nutritional and Metabolic Diseases

Italy, Czechia, Germany, Bulgaria, France, Poland

08/10/2026

Phase IV

An exploratory double-blind randomized placebo-controlled trial to evaluate the effect of ARTENSIUM® cream in the relief of pain in patients with knee osteoarthritis

2026-527647-18-00Knee osteoarthritis is a chronic degenerative joint disease…

Boiron

Musculoskeletal Diseases

France

06/10/2026

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease

2026-525556-28-00Active Primary Sjögren’s Disease

DrugTelitacicept

Vor Biopharma Inc.

Immune System Diseases

Poland, Spain, Hungary, Italy, Netherlands, Romania, Belgium, France, Bulgaria, Germany

06/10/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Idiopathic Hypersomnia (IH) Followed by an Open-label Extension

2025-523822-42-00Idiopathic hypersomnia (IH)

DrugPitolisant

Harmony Biosciences Management Inc.

Nervous System Diseases

France, Germany, Belgium, Spain, Italy, Poland

06/10/2026

Phase III

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment with AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (TE NDMM) (DURGA-6)

2026-525367-40-00Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Melphalan·Lenalidomide

AstraZeneca AB

Neoplasms

Germany, Spain, Norway, Italy, Denmark, France, Poland

06/10/2026

Phase I/II

First-in-human study of ATX-898 as monotherapy and in combination with other anti-neoplastic agents, in participants with advanced solid tumors

2026-526514-85-00Advanced solid tumors

DrugsAbemaciclib·Ribociclib·Fulvestrant

Antares Therapeutics Inc.

Neoplasms

Netherlands, Spain, France, Italy

05/10/2026

Phase III

A Randomized, Double-Blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects with PAH and Functional Limitations Despite Optimized Therapy with Available PAH Medications

2025-524596-24-00Pulmonary Arterial Hypertension (PAH)

DrugTacrolimus

Vivus B.V., Vivus LLC

Respiratory Tract Diseases

Italy, France, Czechia, Poland, Latvia, Germany, Spain

05/10/2026

Phase III

A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine with Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older

2026-526221-18-00COVID-19, Influenza

DrugNaCl

Sanofi Vaccines US Inc.

Virus Diseases

Belgium, Poland, Spain, Portugal, France, Germany

05/10/2026

Phase III

A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)

2025-524067-20-00Primary Biliary Cholangitis (PBC)

DrugSaroglitazar Magnesium

Zydus Therapeutics Inc.

Digestive System Diseases

Ireland, Greece, Estonia, Netherlands, Bulgaria, Slovakia, Poland, Latvia, Croatia, Spain, France, Italy

05/10/2026

Phase III

A randomized, double-blind, placebo-controlled, 2-arm multicenter Phase III study to assess the efficacy and safety of ianalumab in participants with Sjogren's disease with high symptom burden (THALASSA)

2025-522271-29-00Sjögren's disease

DrugsTenofovir Alafenamide·Entecavir·Ianalumab

Novartis Pharma AG

Immune System Diseases

Austria, Portugal, Slovakia, Italy, Poland, Hungary, Spain, Czechia, France, Netherlands, Germany

05/10/2026

Phase II

LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors

2025-524515-37-00Neoplasm malignant

DrugBelzutifan

Merck Sharp & Dohme LLC

Neoplasms

Belgium, Spain, Denmark, Italy, France

05/10/2026

Phase I/II

A Phase Ib/II, open-label, safety and tolerability trial of obrixtamig in combination with ZL-1310 in patients with poorly differentiated NEC

2026-525634-27-00Extrapulmonary neuroendocrine carcinoma of large cell histo…

DrugsZL-1310·Obrixtamig·Tocilizumab·Atezolizumab

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Poland, France, Belgium, Germany, Netherlands, Spain

05/10/2026

Phase III

Multicenter and randomised study on atrial fibrillation prevention after cardiac surgery with a 3-way comparison between standard of care, posterior pericardiotomy and a treatment bundle (colchicine, amiodarone and posterior pericardiotomy) (PREV-AF)

2025-523209-14-00Atrial fibrillation

DrugsAmiodarone Hydrochloride·Bisoprolol·Heparin

Clinique Saint Augustin

Cardiovascular Diseases

France

02/10/2026

Phase IV

PRIMO : Precision immunosuppressive drug monitoring in liver transplantation: a randomized control trial

2025-523563-38-00Immunosuppressive treatment in the context of liver transpl…

DrugTacrolimus

Centre Hospitalier Universitaire De Rennes

Digestive System Diseases

France

01/10/2026

Phase II

Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)

2026-526917-27-00primary or recurrent confirmed papillary bladder cancer (BC)

DrugHexvix

Institut Paoli Calmettes

Neoplasms

France

30/09/2026

Phase IV

Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy - CPI

2026-526866-26-00Non-small cell lung cancer (NSCLC) and Head and neck squamo…

DrugsCetuximab·Gemcitabine·Paclitaxel·Bevacizumab

Centre Antoine Lacassagne

Neoplasms

France

30/09/2026

Phase I

Study of safety and tolerability of BCA101 monotherapy and in combination therapy in patients with EGFR-driven advanced solid tumors

2026-526745-99-00Advanced solid tumors

Bicara Therapeutics Inc.

Neoplasms

Spain, France

30/09/2026

Phase I

A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF MINT91 IN COMBINATION WITH OTHER ANTI-CANCER DRUGS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

2025-521544-38-00LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Chugai Pharmaceutical Co. Ltd.

Neoplasms

France

30/09/2026

Phase I/II

A Phase 1/2, Multicenter, First-in-Human, Dose Escalation and Expansion Study Evaluating CHM-029, as Monotherapy and in Combination with Standard Therapies in Participants with Relapsed or Refractory, or Newly Diagnosed Acute Myeloid Leukemia (AML) with NPM1 Mutations, KMT2A or NUP98 Rearrangements

2026-526409-14-00Acute Myeloid Leukemia

DrugsPosaconazole·Daunorubicin·Cytarabine·Azacitidine

Charm Therapeutics Limited

Neoplasms

France, Germany, Spain, Poland, Netherlands

30/09/2026

Phase I

A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

2024-518348-19-00Advanced bladder cancer, Advanced Breast cancer (HER2+, HR+…

Novartis Pharma AG

Neoplasms

France, Italy, Spain, Portugal, Germany, Belgium

29/09/2026

Phase III

A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)

2026-525265-48-00Pulmonary Arterial Hypertension

DrugTreprostinil Palmitil

Insmed Inc.

Cardiovascular Diseases

Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Poland, Lithuania, Spain, Romania, Greece

29/09/2026

Phase II

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria (PKU)

2026-525622-37-01Phenylketonuria

Maze Therapeutics Inc.

Nutritional and Metabolic Diseases

Germany, France, Netherlands

29/09/2026

Phase III

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

2025-522954-37-00Peripheral Artery Disease

DrugsAmrecibart·Cenvacibart·Rivaroxaban

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands

29/09/2026

Phase III

Assessing the efficacy of vasculoprotective dapagliflozin treatment in septic shock patients with microcirculatory dysfunction (GLIFLOSHOCK)

2025-524820-23-00Septic chock

DrugDapagliflozin

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

28/09/2026

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease

2026-526778-18-00Anemia in subjects with sickle cell disease (SCD)

DrugMitapivat

Agios Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Italy, France, Belgium, Ireland

28/09/2026

Phase III

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

2025-522648-42-01• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent …

DrugsAtumelnant·Hydrocortisone

Crinetics Pharmaceuticals Inc.

Not possible to specify

Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France

28/09/2026

Phase III

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.

DrugDanicamtiv

Kardigan Inc.

Cardiovascular Diseases

Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands

28/09/2026

Phase III

A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)

2026-525886-38-00Inherited retinal dystrophy due to dysfunction in the human…

Atsena Therapeutics Inc.

Eye Diseases

Italy, Germany, Spain, Netherlands, France, Belgium

28/09/2026

Phase III

A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)

2026-525298-38-00generalized Myasthenia gravis

DrugClaseprubart

Dianthus Therapeutics Inc.

Immune System Diseases

Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark

28/09/2026

Phase II

FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations

2026-525763-40-00Patients with previously untreated chronic lymphocytic leuk…

DrugsNemtabrutinib·Obinutuzumab·Venetoclax

French Innovative Leukemia Organization (F.I.L.O.).

Hemic and Lymphatic Diseases

France

25/09/2026

Phase I

A Study to Learn About the Study Medicine Called PF-08032562 in People with Advanced or Metastatic Solid Tumors

2025-524387-38-00metastatic/advanced breast cancer (BC) and colorectal cance…

Pfizer Inc.

Neoplasms

France, Spain

25/09/2026

Phase I/II

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)

2026-527163-15-00Advanced Renal Cell Carcinoma

DrugsCabozantinib·Ipilimumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Ireland, Romania, Italy, Spain, Czechia, Finland, France, Germany

24/09/2026

Phase III

A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).

2025-525030-57-00High-risk muscle invasive urothelial carcinoma (MIUC) origi…

DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Enfortumab Vedotin

AstraZeneca AB

Neoplasms

Italy, Poland, Spain, France, Germany

23/09/2026

Phase III

A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Face and Neck Atopic Dermatitis

2025-525133-31-00Face and Neck Atopic Dermatitis

DrugLebrikizumab

Almirall S.A.

Skin and Connective Tissue Diseases

Poland, Germany, Portugal, France, Spain, Denmark

22/09/2026

Phase IV

A phase IV randomised, parallel-group, double-blinded, placebo-controlled, trial evaluating the efficacy of the tree SLIT-tablet in adolescents (12-17 years of age) with allergic rhinitis/allergic rhinoconjunctivitis induced by birch pollen using an environmental exposure unit.

2026-526861-88-00Moderate to severe allergic rhinitis/allergic rhinoconjunct…

Alk-Abello A/S

Immune System Diseases

France

21/09/2026

Phase II

A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease

2026-525197-19-00Fibrostenosing Crohn’s Disease

DrugOntunisertib

Agomab Spain S.L.U.

Digestive System Diseases

France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands

21/09/2026

Phase III

A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease

2025-524464-38-00Sickle cell disease

Novo Nordisk A/S

Hemic and Lymphatic Diseases

France, Netherlands, Spain, Italy

21/09/2026

Phase III

A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy

2025-523362-25-00Neoplasms, Endometrial

DrugsDoxorubicin·Paclitaxel

Glaxosmithkline Research & Development Limited

Neoplasms

Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia

21/09/2026

Phase III

A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.

2025-523361-25-00Ovarian Neoplasms

DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab

Glaxosmithkline Research & Development Limited

Neoplasms

Denmark, Austria, France, Sweden, Finland, Netherlands, Norway, Czechia, Belgium, Greece, Italy, Germany, Spain

21/09/2026

Phase III

A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)

2025-524493-42-00Idiopathic Pulmonary Fibrosis

DrugsDeupirfenidone·Pirfenidone

Puretech Lyt 100 Inc.

Respiratory Tract Diseases

Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands

18/09/2026

Phase III

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

2025-524202-15-00Recurrent Platinum-Sensitive Ovarian Cancer

DrugsPegfilgrastim·Doxorubicin·Paclitaxel·Bevacizumab

Genmab A/S

Neoplasms

Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland

18/09/2026

Phase III

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)

2025-524405-33-00Choroidal Melanoma

Aura Biosciences Inc.

Neoplasms

Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy

17/09/2026

Phase III

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)

2026-525617-31-00Metastatic Pancreatic Ductal Adenocarcinoma

DrugsGemcitabine·Paclitaxel

Immuneering Corp.

Neoplasms

Spain, Czechia, Hungary, Belgium, Poland, Germany, France, Italy, Romania

17/09/2026

Phase III

A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer

2025-525026-35-00Limited-stage small cell lung cancer (LS-SCLC)

Pharmacosmos A/S

Neoplasms

Czechia, Greece, France, Belgium, Italy, Spain, Germany

17/09/2026

Phase III

Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)

2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria

16/09/2026

Phase III

A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

2026-526654-14-01Newly Diagnosed Multiple Myeloma

DrugsRamantamig·Velcade·Bortezomib·Daratumumab

Janssen Cilag International

Neoplasms

Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain

16/09/2026

Phase III

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis

2025-522393-37-00Autoimmune Hepatitis (AIH)

DrugInebilizumab

Amgen Inc.

Digestive System Diseases

Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain

16/09/2026

Phase III

Randomized double-blinded placebo-controlled study of the efficacy of fluoxetine in add-on treatment of drug-resistant, complex and rare epilepsy in children aged 8 years and older: use of a design evaluating the time to reach a defined number of seizures for each child during the prospective observational phase (FLUOXEPIL)

2024-519897-38-01complex and rare epilepsy in children aged 8 years and older

DrugFluoxetine

Centre Hospitalier Regional De Marseille

Nervous System Diseases

France

15/09/2026

Phase I

A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer

2025-522707-26-00Advanced HR+/HER- breast cancer

Novartis Pharma AG

Neoplasms

Germany, France, Netherlands, Spain, Italy

15/09/2026

Phase II

J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

2026-525480-41-00Pulmonary Disease, Chronic Obstructive

DrugBrenipatide

Eli Lilly & Co.

Respiratory Tract Diseases

Denmark, France, Romania, Czechia, Poland, Hungary, Germany, Austria

15/09/2026

Phase II

Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.

2025-524655-30-00Parkinson’s disease

H. Lundbeck A/S

Nervous System Diseases

Czechia, France, Spain, Poland, Italy, Germany, Sweden

15/09/2026

Phase I

Study of the distribution of linezolid in the prostate in patients who underwent endoscopic prostate enucleation – DiProLine

2026-527015-42-00A Study of the Distribution of Linezolid in the Prostate in…

Centre Hospitalier Le Mans

Male Urogenital Diseases

France

14/09/2026

Phase III

An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).

2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…

Grifols Therapeutics LLC

Immune System Diseases

Italy, Poland, Czechia, France, Spain

14/09/2026

Phase II

A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)

2025-524496-23-00Papulopustular Rosacea (PPR)

DrugRemibrutinib

Novartis Pharma AG

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Italy, Germany

14/09/2026

Phase II

COLIBRI-GI_Randomized phase 2 study of second-line chemotherapy comparing FOLFIRI + ivonescimab versus FOLFIRI + bevacizumab in Microsatellite Stable (MSS)/ proficient MisMatch Repair (pMMR) BRAF wild type (wt) advanced colorectal cancer (mCRC) without liver metastases

2025-524215-36-00Patients with non resectable pMMR/MSS BRAF wt mCRC, without…

DrugsFolinic acid·Ivonescimab·Fluorouracil·Leucovorin

Unicancer

Neoplasms

France

11/09/2026

Phase I

A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS

2026-525888-40-00Advanced solid tumors

Nextcure Inc.

Neoplasms

Italy, Poland, France, Spain

09/09/2026

Phase IV

AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma

2025-524916-13-00Asthma

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

France, Spain, Germany, Italy

09/09/2026

Phase III

C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)

2026-525318-75-00Overweight or Obesity

DrugBerobenatide

Pfizer Inc.

Nutritional and Metabolic Diseases

Spain, France, Germany, Poland, Italy

09/09/2026

Phase IV

Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG

2025-523610-83-00Elderly patients (>70 years old) presenting with cancer and…

DrugsBrigatinib·Pazopanib·Sunitinib·Alectinib

Institut Gustave Roussy

Immune System Diseases

France

08/09/2026

Phase I

A study of IDE892 as monotherapy and combination in MTAP-deleted Advanced Solid Tumors

2025-524715-37-00MTAP-Deleted Advanced Solid Tumors

Ideaya Biosciences Inc.

Diagnosis

Spain, France

08/09/2026

Phase I

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

2025-523601-16-00Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Foll…

Eli Lilly & Co.

Hemic and Lymphatic Diseases

Spain, Poland, Italy, France, Germany

08/09/2026

Phase III

A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)

2026-525489-23-00Relapsed Extensive-Stage Small Cell Lung Cancer After Plat…

DrugsSiltuximab·Tarlatamab

Amgen Inc.

Neoplasms

Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain

08/09/2026

Phase IV

A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome

2025-524649-28-00Cushing's syndrome

DrugOsilodrostat

Recordati AG

Hormonal diseases

Germany, Bulgaria, France, Romania, Italy, Poland, Spain

08/09/2026

Phase I

A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors

2024-519111-34-00Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Canc…

Novartis Pharma AG

Neoplasms

France, Spain, Italy, Germany

08/09/2026

Phase II

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

2026-526218-10-00Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (S…

Argenx

Immune System Diseases

Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria

08/09/2026

Phase III

EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy

2026-525374-19-00Immune system diseases

DrugImiglucerase

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Hungary, Italy, France, Finland, Germany, Spain

08/09/2026

Phase II

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Italy, Spain, Romania, Germany, France

07/09/2026

Phase II

"Evaluation of the impact of the dose of heparin on the occurrence of DWI ischemic lesions after embolization of unruptured intracranial aneurysm" "HARMONI"

2026-526530-13-00Intracranial aneurysms

DrugsAcetylsalicylic acid·Ticagrelor

Centre Hospitalier Universitaire De Bordeaux

Nervous System Diseases

France

07/09/2026

Phase I

A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors

2026-525215-13-00Advanced Solid Tumors

F. Hoffmann-La Roche AG

Neoplasms

Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France

07/09/2026

Phase II

Randomized, Double blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants with Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (Cohort A) and in Cancer Patients at High Risk of Venous Thromboembolism (Cohort B)

2026-525479-15-00Venous Thromboembolism

DrugRBD4059

Ribocure Pharmaceuticals AB

Cardiovascular Diseases

Poland, Romania, France, Bulgaria

04/09/2026

Phase II

BiFAST : A phase II trial evaluating fixed dose and faster ramp-up of epcoritamab with lenalidomide for 3L relapse/refractory large B-cell lymphoma after CAR T-cells therapy in 2nd line

2025-520895-24-003L relapse/refractory large B-cell lymphoma after CAR T-cel…

DrugsEpcoritamab·Lenalidomide

LYSARC

Hemic and Lymphatic Diseases

France

02/09/2026

Phase III

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

2026-525913-30-00Immune system diseases

DrugsBelumosudil·Ixazomib·Imatinib·Sirolimus

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark

02/09/2026

Phase I

A randomized, placebo-controlled trial, to evaluate the safety, immunogenicity and the optimal dose of MOPEVAC-Las vaccine candidate against Lassa Fever, in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase (FIRST-IN-MOP)

2025-524034-26-02Lassa fever

Institut Pasteur

Virus Diseases

France

01/09/2026

Phase I

A study to test how well different doses of BI 4060107 are tolerated by people with advanced cancer (solid tumours)

2026-525187-18-00solid tumours

Aimed Bio lnc.

Neoplasms

France

01/09/2026

Phase I

PRadR 2 - A single center, open-label, Phase I study evaluating 161Tb-PSMA therapy in adult patients with metastatic clear cell renal cell carcinoma

2026-525526-38-00Metastatic clear cell renal cell carcinoma

Centre Leon Berard

Neoplasms

France

01/09/2026

Phase III

Effect of GABAergic treatments on cortical plasticity and motor learning capacity in the subacute phase after stroke: a single-case experimental study (GABAPLAST)

2026-526884-39-00Stroke

DrugGabapentin

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

01/09/2026

Phase II

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Eye Diseases

Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal

01/09/2026

Phase III

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).

2025-524014-29-00Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca AB

Neoplasms

Poland, Italy, Denmark, France, Sweden, Germany, Spain

01/09/2026

Phase II

A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of VQ-101 in participants with Parkinson’s disease carrying a heterozygous mutation of GBA1

2026-525848-15-00GBA1-associated Parkinson’s disease

Vanqua Bio Inc.

Nervous System Diseases

Netherlands, France, Spain, Germany

01/09/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)

DrugEngasertib

Vaderis Therapeutics AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium

31/08/2026

Phase I/II

An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability.

2026-525698-38-00Hearing Loss Related to biallelic pathogenic variation (s) …

Sensorion

Otorhinolaryngologic Diseases

France

31/08/2026

Phase III

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy

2025-523857-32-00Spinal Muscular Atrophy

DrugSalanersen

Biogen Idec Research Limited

Nervous System Diseases

Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland

31/08/2026

Phase III

Evaluation of the Impact of a Strategy of Perioperative NSAID Suppression in Patients Undergoing Video-assisted Thoracic Surgery (VATS) on the Presence of Chronic Postoperative Pain (CPOP): a Randomised Clinical Trial (EVADRAINS)

2025-524917-96-00Thoracic surgery

DrugCalcium

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

31/08/2026

Phase III

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

2025-524263-21-01Resected Stage II-III Kirsten rat sarcoma virus oncogene ho…

DrugsDivarasib·Nivolumab·Pembrolizumab

F. Hoffmann-La Roche AG

Neoplasms

France, Spain, Austria, Greece, Portugal, Ireland, Belgium, Italy, Poland, Germany, Netherlands

28/08/2026

Phase I/II

A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies

2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…

DrugPosaconazole

Institut De Recherches Internationales Servier IRIS

Neoplasms

Netherlands, Spain, Germany, Italy, France, Finland

27/08/2026

Phase III

A multicenter, open-label, single-arm, baseline-controlled trial to assess the efficacy and safety of lucerastat in treatment-naïve/pseudo-naïve adult male participants with Fabry disease

2026-525207-27-00Fabry disease

Idorsia Pharmaceuticals Ltd.

Nutritional and Metabolic Diseases

Germany, France

27/08/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis

2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)

Contineum Therapeutics Inc.

Respiratory Tract Diseases

Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain

26/08/2026

Phase II

C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer

2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…

DrugsPF-08634404·Pemetrexed·Paclitaxel·Carboplatin

Pfizer Inc.

Neoplasms

Spain, France, Italy, Ireland, Germany, Poland

26/08/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

2025-524130-26-00Gastrointestinal Cancers

DrugPegfilgrastim

Genmab A/S

Neoplasms

Italy, Belgium, France, Spain, Denmark, Netherlands, Germany

26/08/2026

Phase II

DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty

2026-525351-81-00chronic thromboembolic pulmonary hypertension

DrugRiociguat

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

25/08/2026

Phase III

Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

2026-525280-40-00Acute ischemic stroke

DrugTenecteplase

Fondation A De Rothschild

Nervous System Diseases

France

25/08/2026

Phase II

[68]GA-FAPI-46 PET/CT for the diagnosis of metastatic lesions in patients with lobular breast cancer (ICL). FAPICL

2025-524897-40-00invasive lobular carcinomas of the breast

Drug[68Ga]Ga-FAPI-46

Hospices Civils De Lyon

Diagnosis

France

25/08/2026

Phase I

A single and multiple ascending dose study of DFL23693 in healthy volunteers

2026-527078-35-00Osteoarthritis

Dompe' Farmaceutici S.p.A.

Musculoskeletal Diseases

France

25/08/2026

Phase I

A Phase 1 Study of CTIM-76 in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

2025-523968-20-00Patients with Recurring Ovarian Cancer and Other Advanced S…

Context Therapeutics Inc.

Neoplasms

France, Spain

25/08/2026

Phase III

A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis

2025-524757-14-00Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma

Immune System Diseases

Hungary, France, Greece, Poland, Spain, Italy, Germany

25/08/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension

2025-523821-17-00narcolepsy

DrugPitolisant

Harmony Biosciences Management Inc.

Nervous System Diseases

Belgium, Italy, Germany, France, Spain, Poland

25/08/2026

Phase II

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

2025-524793-42-00Relapsed/Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Sweden, Spain, Greece, Portugal, France, Hungary

25/08/2026

Phase II

Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)

2025-524905-34-00Solid tumor

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania

25/08/2026

Phase I

Proof of cOncept Study demonStrating the potential substitutIon of suBcutaneous Injection of recombinant human insulin by subLIngual administration of S.L.I.M®-Formulations in TYpe-I DIABEtic PaTiEntS

2025-524539-38-01Patients with diabete type 1 under pump

Sublin B.V.

Nutritional and Metabolic Diseases

France

24/08/2026

Phase III

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Etifoxine Monotherapy in The Treatment of Adjustment Disorder with Anxiety (ADWA)

2025-524287-38-00Treatment of adjustment disorder with anxiety (ADWA).

Biocodex

Nervous System Diseases

Bulgaria, France, Romania, Czechia

24/08/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

2025-524928-21-00Pancreatic Adenocarcinoma

DrugRMC-9805

Revolution Medicines Inc.

Neoplasms

Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark

24/08/2026

Phase III

FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial

2025-521663-13-00Women aged 75 years or older presenting with E. coli pyelon…

DrugsCefotaxime·Ertapenem·Ceftazidime·Aztreonam

Assistance Publique Hopitaux De Paris

Female Urogenital Diseases and Pregnancy Complications

France

21/08/2026

Phase III

Surgery versus intra-lesional sclerosis with polidocanol (Aetoxisclerol) in labial venous malformations in children and adults: a randomized controlled trial - SASOV

2025-521374-34-00superficial labial venous malformation

Centre Hospitalier Regional Universitaire De Tours

Cardiovascular Diseases

France

21/08/2026

Phase III

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

2025-524669-25-00Polycythemia Vera

Deciphera Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland

21/08/2026

Phase III

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

2025-524934-24-00Neoplasms, Gastrointestinal Stromal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary

21/08/2026

Phase III

A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

2025-524641-27-00High-Grade Serous Ovarian, Fallopian Tube, or Primary Perit…

DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel

K-Group Beta Inc.

Neoplasms

Germany, Spain, Italy, Belgium, Poland, France, Ireland

21/08/2026

Phase III

A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

2025-523252-31-00High Risk Smoldering Multiple Myeloma (HR-SMM)

DrugsLinvoseltamab·Daratumumab

Regeneron Pharmaceuticals Inc.

Neoplasms

Italy, Spain, Poland, France, Norway, Greece, Germany

20/08/2026

Phase III

A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR

2026-525296-60-00Stargardt Disease (STGD1)

Alkeus Pharmaceuticals Inc.

Eye Diseases

Belgium, France, Spain, Italy, Germany

20/08/2026

Phase I/II

Phase I/II trial of Dinutuximab beta in combination with Irinotecan and Rapamycin in pediatric, adolescents and adult patients with relapsed/refractory bone tumors. BONE DINIRRA

2026-525463-40-00osteosarcomas, chondrosarcomas, Ewing sarcomas, Ewing-like …

DrugsDinutuximab Beta·Sirolimus·Irinotecan

Les Hopitaux Universitaires De Strasbourg

Neoplasms

France

20/08/2026

Phase II

Treatment of post-traumatic stress disorder with medical nitrous oxide combined with exposure to a personal traumatic script: a multicenter randomized controlled trial (POTESTA)

2026-525826-39-00Post-Traumatic Stress Disorder

Centre Hospitalier Regional Universitaire De Tours

Mental Disorders

France

19/08/2026

Phase I/II

A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

2025-525036-34-00Solid Tumours

DrugsImlunestrant·Fulvestrant

Terremoto Biosciences Inc.

Neoplasms

Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland

18/08/2026

Phase III

Evaluation of an asPirin-free strategy with ticAgrelor in patieNTs witH a myocardial infarction treatEd medically alONe (PANTHEON)

2025-525159-20-00myocardial infarction

DrugsAcetylsalicylic acid·Ticagrelor

Montreal Heart Institute

Cardiovascular Diseases

France

18/08/2026

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis

2025-524756-54-00Ocular Myasthenia Gravis

DrugRozanolixizumab

UCB Biopharma

Immune System Diseases

Hungary, Greece, Italy, Spain, Germany, Poland, France

18/08/2026

Phase II

A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab

2025-524591-30-00Hepatocellular Carcinoma

Akeso Biopharma Co. Ltd.

Neoplasms

Poland, France, Spain, Italy

18/08/2026

Phase III

Evaluation of the efficacy of intravenous lidocaine on chronic postoperative pain in patients requiring emergency abdominal surgery. Randomized, double-blind, controlled, multicenter study – LIDOC-POPEYE.

2025-523682-24-00emergency abdominal surgery

Centre Hospitalier Universitaire De Nantes

Anesthesia and Analgesia

France

17/08/2026

Phase II

FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML

2025-523632-39-00acute myeloid lymphoma

DrugsCiclosporin·Treosulfan·Mycophenolate Mofetil·Fludarabine

Institut Paoli Calmettes

Neoplasms

France

17/08/2026

Phase II

Efficacy of rituximab for remission maintenance in patients with primary angiitis of the central nervous system: an open-label, randomized, controlled trial comparing systematic rituximab infusions and azathioprine - MAINRIPAC

2026-525394-39-00Patients with primary angiitis of the central nervous system

DrugsAzathioprine·Rituximab

Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

Nervous System Diseases

France

17/08/2026

Phase I

A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

2025-524080-20-00Metastatic castration resistant prostate cancer

Novartis Pharma AG

Neoplasms

France, Italy, Spain, Germany

17/08/2026

Phase I/II

A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

2025-524915-36-00Lymphoma, Non-Hodgkin

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Germany, Spain, Finland, France

17/08/2026

Phase II

TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations

2026-525336-41-00Interstitial Lung Disease

DrugsAzithromycin·Hydroxychloroquine·Prednisolone·Prednisone

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

14/08/2026

Phase I

A Phase 1b Study of ZN-c3 in Combination with Chemotherapy or Bevacizumab in Subjects with Ovarian, Peritoneal, or Fallopian Tube Cancer

2025-524868-38-00Ovarian, Peritoneal, or Fallopian Tube Cancer

K-Group Beta Inc.

Neoplasms

France

13/08/2026

Phase II

Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)

2024-518027-30-00leptospirosis

DrugDoxycycline

CHU De Martinique

Bacterial Infections and Mycoses

France

13/08/2026

Phase III

SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients

2025-523444-12-00Breast Cancer

AstraZeneca AB

Neoplasms

Poland, Spain, France, Germany, Italy

13/08/2026

Phase I

A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors

2025-524805-34-00Locally Advanced or Metastatic Solid Tumors

Exelixis Inc.

Neoplasms

Italy, Netherlands, France, Spain

11/08/2026

Phase I

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

2025-522532-14-00Advanced solid tumors

Pfizer Inc.

Neoplasms

Netherlands, France, Spain

11/08/2026

Phase II

SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics

2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication

Assistance Publique Hopitaux De Paris

Hormonal diseases

France

10/08/2026

Phase III

AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial

2025-524584-20-00Premature ventricular contractions (PVC)

DrugsBisoprolol·Flecainide

Assistance Publique Hopitaux De Paris

Cardiovascular Diseases

France

10/08/2026

Phase II

A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study

2026-526775-27-00Wet Age-Related Macular Degeneration (wAMD) Patients

DrugAflibercept

Laboratoires Kol

Eye Diseases

France

10/08/2026

Phase I

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

2026-525217-31-00Myeloproliferative Neoplasms

Incyte Corp.

Neoplasms

Italy, Belgium, Germany, France, Spain

10/08/2026

Phase I

A Phase 1 Trial of GEN1119 in Participants with Solid Tumors

2026-525610-62-00Solid Tumors

Genmab A/S

Neoplasms

Spain, France

10/08/2026

Phase III

A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of atrasentan in pediatric patients of 2 to <18 years of age with primary immunoglobulin A nephropathy (IgAN)

2025-522824-29-00Primary IgAN

DrugAtrasentan

Novartis Pharma AG

Immune system processes

France, Spain

10/08/2026

Phase III

Efficacy and safety of once daily oral semaglutide in adults with overweight or obesity

2025-524626-18-00Overweight and obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden

10/08/2026

Phase III

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs

2025-523333-26-00Graves' Disease (GD)

Argenx

Hormonal diseases

Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria

07/08/2026

Phase III

Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)

2025-520678-20-00Adult patients with symptomatic and inflammatory Hand osteo…

DrugClobetasol Propionate

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

07/08/2026

Phase IV

HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial

2025-524845-28-00Cytomegalovirus infection in solid-organ transplant recipie…

DrugEverolimus

Centre Hospitalier Universitaire Vaudois

Virus Diseases

France, Spain

07/08/2026

Phase III

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

2025-522819-42-01sepsis

DrugsCefotaxime·Ceftazidime·Meropenem·Amoxicillin

Centre Hospitalier Universitaire De Rennes

Bacterial Infections and Mycoses

France

06/08/2026

Phase II

VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study

2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…

DrugVerapamil

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

05/08/2026

Phase III

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment

2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…

DrugBenralizumab

AstraZeneca AB

Respiratory Tract Diseases

Denmark, Belgium, France, Italy, Netherlands, Austria, Poland

04/08/2026

Phase II

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

2025-525016-41-00Idiopathic Pulmonary Fibrosis

AstraZeneca AB

Respiratory Tract Diseases

Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark

04/08/2026

Phase III

RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»

2025-521591-64-00Adult patients with a diagnosis of fibrotic Hypersensitivit…

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

03/08/2026

Phase III

A Randomized Phase 2/3 Study Evaluating the Safety and Efficacy of Pivekimab Sunirine (PVEK) in Combination with Venetoclax and Azacitidine in Adult Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) Ineligible to Receive Intensive Chemotherapy

2025-523724-47-00Acute Myeloid Leukemia

DrugsPivekimab Sunirine·Azacitidine·Venetoclax

AbbVie Deutschland GmbH & Co. KG

Neoplasms

France, Austria, Spain

03/08/2026

Phase III

A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

2025-523884-39-00Systemic sclerosis

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Skin and Connective Tissue Diseases

Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania

03/08/2026

Phase III

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

2026-525922-39-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece

03/08/2026

Phase III

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

2026-525923-26-00Moderately to Severely Active Ulcerative Colitis

DrugsJNJ-78934804·Guselkumab

Janssen Cilag International

Immune System Diseases

France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal

03/08/2026

Phase II

A Multicenter, Open-Label, Long-Term, Safety and Tolerability Extension Study of PTI5803 as adjunctive therapy in patients ≥ 14 years of age with drug-resistant seizures associated to focal cortical dysplasia.

2026-525161-40-00Drug resistant focal epilepsy related to focal cortical dys…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

31/07/2026

Phase I/II

A Phase 1b/2a first-in-human, multicentre, randomized, double-blind, placebo-controlled study of multiple ascending dose (Part1) followed by an open-label extension (Part2) to assess the safety, tolerability, and pharmacokinetics of intrathecally administered S233107 in participants with spinocerebellar ataxia type 3

2025-525111-17-00Spinocerebellar ataxia type 3

Institut De Recherches Internationales Servier IRIS

Nervous System Diseases

France, Denmark, Spain, Portugal

30/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …

AstraZeneca AB

Cardiovascular Diseases

Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia

29/07/2026

Phase II

A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer

2026-525382-47-00Small Cell Lung Cancer (SCLC)

DrugPaclitaxel

Puma Biotechnology Inc.

Neoplasms

France, Poland, Spain

28/07/2026

Phase IV

Comparative study of two vaccination schedules for the subunit Herpes Zoster vaccine in Multiple Sclerosis and Neuromyelitis optica spectrum disease patients treated with anti-CD20 therapy: an open-label randomised controlled trial.

2025-525106-37-00Multiple Sclerosis and Neuromyelitis optica spectrum

DrugsOcrelizumab·Rituximab

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

28/07/2026

Phase II

OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial

2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

28/07/2026

Phase I

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer

2025-522209-40-00Ovarian Cancer

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Denmark, Spain, France

27/07/2026

Phase I

A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms

2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…

Prelude Therapeutics Inc.

Neoplasms

Italy, France, Spain

27/07/2026

Phase II

A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)

2025-522757-19-00LOCALLY ADVANCED OR METASTATIC ADRENOCORTICAL CARCINOMA

Cancer Research UK

Neoplasms

Spain, France, Germany, Norway

27/07/2026

Phase III

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

2025-522488-14-00Participants with obesity with or without type 2 diabetes

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium

27/07/2026

Phase III

4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome

2025-523837-25-00Barth Syndrome

DrugElamipretide

Stealth Biotherapeutics Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Ireland, Netherlands, France, Italy

27/07/2026

Phase III

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)

2025-523819-11-00Small Cell Lung Cancer

DrugsABBV-706·Topotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Italy, Greece, Spain, Belgium, France, Austria, Germany

27/07/2026

Phase III

An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease

2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer

BeOne Medicines I GmbH

Neoplasms

Poland, Italy, Germany, France, Spain

27/07/2026

Phase II

Evaluation of the effect of botulinum toxin on refractory upper limb rest tremor in parkinsonian patients, double-blind, placebo-controlled cross-over study : TOX PARK

2026-525862-23-00parkinson disease

DrugsDysport·NaCl

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

24/07/2026

Phase II

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

2025-525040-18-00triple‑negative breast cancer

DrugsEndoxan·Paclitaxel·Pembrolizumab

Institut Paoli Calmettes

Neoplasms

France

24/07/2026

Phase II

functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study

2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis

Centre Jean Perrin

Not possible to specify

France

24/07/2026

Phase III

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam

2025-524054-34-00Spinal Muscular Atrophy

DrugSalanersen

Biogen Idec Research Limited

Nervous System Diseases

Finland, Spain, Italy, Poland, Ireland, Germany, France

24/07/2026

Phase III

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)

2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…

DrugsElecoglipron·Dapagliflozin

AstraZeneca AB

Cardiovascular Diseases

Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany

24/07/2026

Phase I/II

A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC

2025-524418-27-00Advanced ALK-positive NSCLC

Triana Biomedicines Inc.

Respiratory Tract Diseases

France, Italy, Germany, Spain

22/07/2026

Phase I

Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Spain, France, Italy

21/07/2026

Phase III

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis

2026-525242-29-00Primary Sclerosing Cholangitis

DrugElafibranor

Ipsen Bioscience Inc.

Digestive System Diseases

Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway

21/07/2026

Phase I/II

A Phase 1/2 First-Time-in-Human, open-label, multicenter, dose escalation and dose optimization study of GSK5471713 in adult participants with metastatic castration resistant prostate cancer (mCRPC).

2025-523874-17-00Neoplasms, Prostate

Glaxosmithkline Research & Development Limited

Neoplasms

Netherlands, France, Spain

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens

2025-524336-19-00HIV-1

DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF

Gilead Sciences Inc.

Virus Diseases

Poland, Italy, France, Spain, Germany, Netherlands

21/07/2026

Phase III

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

2025-524335-39-00HIV-1

DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir

Gilead Sciences Inc.

Virus Diseases

Netherlands, Poland, Germany, France, Spain, Italy

21/07/2026

Phase III

A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period

2025-524873-17-00Lichen Sclerosus

DrugDelgocitinib

Leo Pharma A/S

Skin and Connective Tissue Diseases

Italy, France, Spain, Poland, Germany

21/07/2026

Phase II

J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

2025-523258-15-00Breast Neoplasms

DrugsGoserelin·Tamoxifen

Eli Lilly & Co.

Neoplasms

Belgium, France, Italy, Germany

21/07/2026

Phase II

DOXYCYCLINE PENETRATION INTO BONE AND JOINT.

2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…

DrugDoxycycline

Centre Hospitalier Universitaire De Caen Normandie

Bacterial Infections and Mycoses

France

20/07/2026

Phase II

A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

AstraZeneca AB

Cardiovascular Diseases

Germany, Italy, Spain, France, Sweden

20/07/2026

Phase III

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

2025-522227-99-00Huntington’s Disease

DrugVotoplam

Novartis Pharma AG

Nervous System Diseases

Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary

20/07/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-524711-36-00Narcolepsy Type 1

DrugALKS 2680

Alkermes Inc.

Nervous System Diseases

Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland

20/07/2026

Phase II

A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.

2026-525162-21-00Drug resistant seizures associated to Focal Cortical Dyspla…

DrugPTI5803

PannTheraPi

Nervous System Diseases

France

20/07/2026

Phase II

SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms

2025-523840-11-00Children with refractory symptoms

DrugMidazolam

Centre Leon Berard

Pathological Conditions, Signs and Symptoms

France

17/07/2026

Phase III

FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria

2026-525972-25-00Febrile male urinary tract infections caused by Escherichia…

DrugsFosfomycin·Ciprofloxacin·Levofloxacin

Assistance Publique Hopitaux De Paris

Male Urogenital Diseases

France

16/07/2026

Phase II

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

2025-523482-23-00neoplastic pleural effusion

Hospices Civils De Lyon

Neoplasms

France

16/07/2026

Phase III

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

2025-525020-99-00Breast Cancer

University Hospital Of Clermont-Ferrand

Not possible to specify

France

16/07/2026

Phase II

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy

DrugObinutuzumab

Assistance Publique Hopitaux De Paris

Pathological Conditions, Signs and Symptoms

France

15/07/2026

Phase III

The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.

2025-524463-20-00Asthma

DrugsDopamine·Depemokimab

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy

14/07/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-755 in Acute Ischemic Stroke

2025-522734-31-00Acute Ischemic Stroke

Takeda Development Center Americas Inc.

Nervous System Diseases

Greece, Belgium, France, Germany

14/07/2026

Phase III

A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

2025-524648-37-00Metastatic colorectal cancer

Merck Healthcare KGaA

Neoplasms

Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria

14/07/2026

Phase III

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

2025-524448-36-00Focal segmental glomerulosclerosis (FSGS)

DrugPegcetacoplan

Apellis Pharmaceuticals Inc.

Female Urogenital Diseases and Pregnancy Complications

France, Portugal, Spain, Slovakia, Italy, Germany, Poland

14/07/2026

Phase III

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

2025-525088-34-00Metastatic Pancreatic Adenocarcinoma

Revolution Medicines Inc.

Digestive System Diseases

Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain

14/07/2026

Phase II

A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease

2025-524139-38-00Antibody-mediated Kidney Disease

DrugSurovatamig

AstraZeneca AB

Immune System Diseases

France, Germany, Italy, Belgium, Poland, Spain

13/07/2026

Phase I/II

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

2025-525105-20-00Multiple Myeloma (MM), Multiple Myeloma (MM)

DrugEtentamig

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy

13/07/2026

Phase I

A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

2026-525234-39-00Relapsed or Refractory acute myeloid leukemia, Relapsed or …

Janssen Cilag International

Neoplasms

France, Spain, Germany, Denmark, Belgium

13/07/2026

Phase II

A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement

2025-523923-22-00Previously Treated, Unresectable, Locally Advanced or Metas…

Elevar Therapeutics Inc.

Neoplasms

France, Spain

09/07/2026

Phase III

Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)

2023-505575-69-01Osteosarcoma

DrugCabozantinib

Institut Gustave Roussy

Neoplasms

Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain

08/07/2026

Phase II

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Belgium, Ireland, Germany, Norway, Italy, France, Spain

07/07/2026

Phase I/II

A PHASE 1/2 STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFECTS ON CLINICAL OUTCOMES OF PEGTIBATINASE (TVT-058) ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH CYSTATHIONINE BETASYNTHASE-DEFICIENT HOMOCYSTINURIA (COMPOSE)

2023-509074-31-00Classical Homocystinuria

DrugPegtibatinase

Travere Therapeutics Switzerland GmbH, Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

France

07/07/2026

Phase III

C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…

Pfizer Inc.

Neoplasms

France, Spain, Italy

07/07/2026

Phase III

A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)

2025-523369-32-00Fibrosing interstitial lung disease

DrugNerandomilast

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Respiratory Tract Diseases

Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal

07/07/2026

Phase III

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy

2025-524028-23-00Multiple Myeloma

F. Hoffmann-La Roche AG

Neoplasms

France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland

07/07/2026

Phase III

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

2025-522563-15-00Metastatic Pancreatic Ductal Adenocarcinoma; PDAC

DrugsCalcium folinate·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Portugal, Spain, France, Italy, Germany, Austria

06/07/2026

Phase II

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Mediar Therapeutics Inc.

Immune System Diseases

Netherlands, Romania, Poland, France, Italy, Spain

06/07/2026

Phase III

TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer

2025-524213-84-00Patients with advanced or metastatic ER+ HER2- breast cancer

DrugsCamizestrant·Abemaciclib

Unicancer

Neoplasms

France

06/07/2026

Phase III

Macroleave: Impact of discontinuation of long-term macrolides in stable Non Cystic Fibrosis Bronchiectasis : a multicenter randomized controlled trial

2025-521493-33-00bronchiectasis unrelated to cystic fibrosis

DrugAzithromycin

Centre Hospitalier Intercommunal Creteil

Respiratory Tract Diseases

France

06/07/2026

Phase II

Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial RSVaxID

2025-524374-42-00allogeneic haematopoietic stem cell transplant recipient, l…

DrugVaxzevria

Hospices Civils De Lyon

Surgical Procedures, Operative

France

06/07/2026

Phase II

Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)

2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…

Assistance Publique Hopitaux De Paris

Therapeutics

France

06/07/2026

Phase III

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

2024-518016-39-00Respiratory tract diseases

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France

06/07/2026

Phase I/II

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination with mFOLFOX6 or FOLFIRI in Patients with Solid Tumors

2026-525629-20-00Solid tumors

Larkspur Biosciences Inc.

Neoplasms

France

03/07/2026

Phase II

Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment

2025-523921-17-00myeloproliferative neoplasms

DrugAnakinra

Centre Hospitalier Regional Et Universitaire De Brest

Hemic and Lymphatic Diseases

France

02/07/2026

Phase II

18F-fluoro-ethyl-tyrosine (18FET) PET for difficult clinical situations in functional pituitary adenoma. A prospective, single arm, single center study. (FET-PIT)

2025-523829-17-00Patients (male or female) ≥18 years old with Suspected func…

Centre Hospitalier Universitaire De Lille

Diagnosis

France

02/07/2026

Phase II

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

2025-522801-39-00Stage III Non Small Cell Lung Cancer

DrugDurvalumab

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

02/07/2026

Phase I/II

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients with DLL3 Expressing Tumors Including Small Cell Lung Cancer

2025-523438-24-00DLL3 Expressing Tumors Including Small Cell Lung Cancer

DrugDurvalumab

Ideaya Biosciences Inc.

Neoplasms

France, Spain

01/07/2026

Phase III

"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"

2025-523815-12-00Relapsed or Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Poland, Spain, Czechia, France, Italy, Germany, Greece

01/07/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)

DrugBevacizumab

Genmab A/S

Neoplasms

Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland

01/07/2026

Phase I/II

A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

2025-522723-98-00solid tumor

DrugsKB707·Docetaxel

Krystal Biotech Inc.

Neoplasms

France, Spain

30/06/2026

Phase III

Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)

2023-508533-14-00Eosinophilic Disease

DrugBenralizumab

AstraZeneca AB

Immune System Diseases

Poland, Netherlands, France

30/06/2026

Phase III

A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection

2025-521971-29-00Non Small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Respiratory Tract Diseases

Spain, Belgium, France, Italy, Germany

30/06/2026

Phase III

A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…

DrugTreprostinil Palmitil

Insmed Inc.

Respiratory Tract Diseases

Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania

30/06/2026

Phase I/II

Phase 1-2, Open-Label, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION337 in Patients with Dravet Syndrome

2025-523835-20-00Dravet Syndrome

Ionis Pharmaceuticals Inc.

Nervous System Diseases

Spain, France, Belgium, Portugal, Germany

30/06/2026

Phase III

A Phase 2/3 Study to Characterize and Evaluate the Efficacy, Safety, and Tolerability of hu14.18K322A Treatment Given in Combination with Chemotherapy in Participants with High-Risk Neuroblastoma

2025-524397-42-00Participants with relapsed HRNB and participants with HRNB…

DrugsTemozolomide·Irinotecan

Renaissance Pharma Limited

Nervous System Diseases

France, Spain, Denmark, Ireland, Germany

30/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

2025-524855-30-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

Merck Healthcare KGaA

Skin and Connective Tissue Diseases

Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia

29/06/2026

Phase III

2025-523871-44-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…

DrugEnpatoran

Merck Healthcare KGaA

Immune System Diseases

Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece

29/06/2026

Phase III

Methoxyflurane versus Standard Care for Non-Traumatic Pain in the Emergency Department (PAIN-THROX) : A Multicenter, Randomized, Controlled, Superiority Trial

2025-525001-21-00Non-traumatic pain

DrugMethoxyflurane

Centre Hospitalier Regional Universitaire De Tours

Not possible to specify

France

29/06/2026

Phase II

C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Spain

29/06/2026

Phase II

Randomised open-label pilot Study on Thiamine supplementation to REduce braiN injury associated with chronic Alcohol use in outpatients with alcohol use disorder : STRENA

2025-524148-36-00Alcoholism

DrugThiamine

Institut National De La Sante Et De La Recherche Medicale

Mental Disorders

France

29/06/2026

Phase I/II

A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors

2025-524623-50-00Solid Tumors

DrugsElironrasib·RMC-9805·Erbitux·Ivonescimab

Revolution Medicines Inc.

Neoplasms

France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium

29/06/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

2025-525009-18-00Pancreatic Ductal Adenocarcinoma

Incyte Corp.

Neoplasms

Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria

26/06/2026

Phase I

A Phase 1 Study of BMS-986460 in Metastatic Castration-resistant Prostate Cancer

2024-513987-24-00Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France

26/06/2026

Phase II

An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration

2025-525008-12-00Geographic atrophy secondary to age-related macular degener…

PulseSight Therapeutics

Eye Diseases

France

25/06/2026

Phase IV

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

2026-525181-22-00prostate cancer

DrugPiflufolastat

Centre Hospitalier Universitaire De Toulouse

Diagnosis

France

25/06/2026

Phase III

A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS

2025-523726-40-00Multiple Sclerosis

F. Hoffmann-La Roche AG

Immune System Diseases

Spain, France, Poland, Italy

24/06/2026

Phase III

Women victims of violences : PTSD treatment by traumatic memory reactivation under the influence of propranolol (VIOFEM)

2025-523107-30-01Post-traumatic stress disorder (PTSD)

DrugPropranolol

Centre Hospitalier Universitaire De Toulouse

Mental Disorders

France

24/06/2026

Phase I

THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom

2025-523305-15-00Patients affected by IPEX syndrome, proven by molecular di…

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

24/06/2026

Phase II

A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants with Non-Cystic Fibrosis Bronchiectasis (NCFB).

2025-523403-29-00Non-cystic fibrosis bronchiectasis

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Poland, Spain, France, Netherlands, Germany

23/06/2026

Phase III

Multicenter Interventional Study Somatrogon Impact on Outcomes in Naive Small for Gestational Age or Idiopathic Short Stature paediatric patients compared with daily growth hormone

2025-523832-38-00Small for gestational age (SGA) and idiopathic short statur…

DrugsSomatrogon·Somatropin

Schneider Children's Medical Center Of Israel

Musculoskeletal Diseases

Greece, Poland, France, Czechia

23/06/2026

Phase III

ECSIP : Early Corticosteroids in Severe Influenza Pneumonia, a phase III randomized controlled trial

2025-524976-40-00patients with influenza-induced acute hypoxemic respiratory…

DrugDexamethasone

Centre Hospital Region Metz Thionville

Respiratory Tract Diseases

France

23/06/2026

Phase II

An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

2025-524164-37-00Relapsing-Remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

F. Hoffmann-La Roche AG

Nervous System Diseases

Poland, Germany, France

23/06/2026

Phase III

A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema

2025-521353-16-00Hereditary Angioedema

DrugDopamine

Adarx Pharmaceuticals Inc.

Immune System Diseases

Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia

22/06/2026

Phase I/II

Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular carcinoma treated with selective internal radiotherapy

2026-526324-48-00HCC – Hepatocellular Carcinoma

Centr Georges Francois Leclerc

Neoplasms

France

22/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia

22/06/2026

Phase II

An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).

2025-524488-18-00Muscle-invasive Bladder Cancer

Astellas Pharma Global Development Inc.

Neoplasms

Germany, France, Poland, Italy, Spain

22/06/2026

Phase II

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00Colitis ulcerative

Merck Sharp & Dohme LLC

Digestive System Diseases

Italy, Greece, Netherlands, Poland, Germany, France

22/06/2026

Phase II

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

2025-524713-88-00Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Verastem Inc.

Neoplasms

France

22/06/2026

Phase IV

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

2025-522275-28-00Metachromatic leukodystrophy

Orchard Therapeutics (Europe) Limited

Musculoskeletal Diseases

Netherlands, Germany, Italy, Sweden, France

22/06/2026

Phase II

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

2025-522587-33-00Narcolepsy with Cataplexy (NT1)

Takeda Development Center Americas Inc.

Nervous System Diseases

Spain, Italy, France

22/06/2026

Phase II

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)

2025-522951-24-00Osteogenesis Imperfecta

DrugAGA2115

Angitia Inc. Ltd.

Musculoskeletal Diseases

Netherlands, France, Denmark

22/06/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)

2025-524337-11-00Systemic Sclerosis

DrugsNintedanib·Tocilizumab·Fludarabine·Rituximab

Celgene Corp.

Immune System Diseases

Spain, Germany, France, Italy, Belgium

19/06/2026

Phase I

A Phase 1 first-in-human study to evaluate SAR448272 in adult participants

2026-526014-87-00healthy volunteers, immunological diseases

Sanofi-Aventis Recherche & Developpement

Immune System Diseases

Germany, Czechia, France, Italy

19/06/2026

Phase I/II

Long-term Follow-up (LTFU) Study of Participants in any iECURE Protocol Using an Investigational Product

2024-514190-21-00Ornithine Transcarbamylase Deficiency (OTC)

Iecure Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, France, Slovenia

18/06/2026

Phase II

A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)

2024-513496-40-00PARKINSON’S DISEASE

DrugPrasinezumab

Universitaetsklinikum Tuebingen AöR

Nervous System Diseases

Spain, Germany, Italy, Sweden, France, Luxembourg

18/06/2026

Phase II

Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial

2025-524889-25-00Osteoporotic Fracture

University Hospital Of Clermont-Ferrand

Musculoskeletal Diseases

France

17/06/2026

Phase IV

STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial

2026-525643-32-00ulcerative colitis

DrugsFilgotinib·Tofacitinib·Upadacitinib

Centre Hospitalier Regional De Marseille

Digestive System Diseases

France

17/06/2026

Phase III

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…

DrugAdmilparant

Bristol-Myers Squibb Services Unlimited Company

Respiratory Tract Diseases

Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany

17/06/2026

Phase II

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period

2025-522294-11-00Systemic sclerosis

Galderma S.A.

Skin and Connective Tissue Diseases

Poland, Italy, Bulgaria, France, Greece, Spain, Croatia

17/06/2026

Phase I

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer

2025-524690-16-00Solid Tumors

Theras Inc.

Neoplasms

Spain, Italy, France

16/06/2026

Phase III

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, E…

AstraZeneca AB

Neoplasms

France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands

16/06/2026

Phase III

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

2025-522643-18-00Stage I NSCLC

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene

Merck Sharp & Dohme LLC

Neoplasms

Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain

16/06/2026

Phase II

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)

DrugsSPYPBO-101·SPY001·SPY002·SPY003

Spyre Therapeutics Inc.

Digestive System Diseases

Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania

16/06/2026

Phase III

Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms

2025-524344-35-00Heart failure

DrugAcetazolamide

Centre Hospitalier Universitaire De Montpellier

Cardiovascular Diseases

France

15/06/2026

Phase III

A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of each of two dose levels of sarilumab in adults with early polymyalgia rheumatica

2024-511296-15-00Musculoskeletal diseases

Sanofi-Aventis Recherche & Developpement

Musculoskeletal Diseases

France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain

15/06/2026

Phase IV

Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)

2025-524487-37-00Primary Immune Complex Membranoproliferative Glomerulonephr…

DrugPegcetacoplan

Swedish Orphan Biovitrum AB (publ)

Immune System Diseases

France, Italy, Spain, Germany, Austria, Belgium, Czechia

15/06/2026

Phase II

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

2025-523616-36-00Transthyretin cardiac amyloidosis

Centre Hospitalier Universitaire De Nantes

Diagnosis

France

13/06/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)

2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Neoplasms

Italy, Netherlands, France, Germany, Spain, Poland, Greece

12/06/2026

Phase I

A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants.

2026-526411-11-00Not applicable for phase I study

Antabio

Not possible to specify

France

12/06/2026

Phase III

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

2025-522267-15-00Relapsed/refractory B-cell Acute Lymphoblastic Leukemia

DrugsMK-1045·Blinatumomab·Tocilizumab

Merck Sharp & Dohme LLC

Neoplasms

Greece, Netherlands, Sweden, France, Italy, Spain, Denmark

12/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria

12/06/2026

Phase II

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic g…

Gilead Sciences Inc.

Neoplasms

Spain, France

11/06/2026

Phase I/II

ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

2025-524728-22-01Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Assistance Publique Hopitaux De Paris

Not possible to specify

France

10/06/2026

Phase III

First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET)

2025-523593-16-00Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stag…

DrugsTemozolomide·Capecitabine

Institut Gustave Roussy

Neoplasms

France

10/06/2026

Phase II

J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis, Acti…

Eli Lilly & Co.

Digestive System Diseases

Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania

10/06/2026

Phase III

Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

2026-526212-37-00Advanced lymphoid leukemia

Institut De Recherches Internationales Servier IRIS

Neoplasms

France

09/06/2026

Phase III

A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.

2025-522777-10-00Follicular Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Germany, Greece, Italy, Poland

09/06/2026

Phase I/II

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors

2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors

Verastem Inc.

Neoplasms

Italy, France, Germany, Belgium, Spain, Netherlands

09/06/2026

Phase III

A Phase 2b/3, Randomized, Double-Blinded, Placebo Controlled Study ChecKing the Efficacy and Safety of ATAciguat to Slow the Progression of VaLvular DYsfunction in Participants with Moderate Calcific Aortic Valve STenosis (KATALYST-AV)

2025-522176-86-01Moderate Calcific Aortic Valve Stenosis (CAVS)

Kardigan Inc.

Cardiovascular Diseases

Norway, Czechia, Portugal, Austria, Poland, France, Spain

08/06/2026

Phase I/II

A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer

2025-521032-11-00Small cell lung cancer extensive stage

Merck Sharp & Dohme LLC

Neoplasms

Germany, Poland, Greece, Italy, France, Spain

08/06/2026

Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

2026-525700-10-00Schizophrenia

Syremis Therapeutics Ltd.

Mental Disorders

France

08/06/2026

Phase II

A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period

2025-522301-37-00Nonsegmental vitiligo

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, Netherlands, France, Italy

08/06/2026

Phase II

A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).

2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Gilead Sciences Inc.

Neoplasms

Spain, Italy, France

08/06/2026

Phase III

A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer

2025-522818-23-00Small Cell Lung Cancer (SCLC)

DrugsZL-1310·Topotecan

Zai Lab (US) LLC

Neoplasms

Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France

08/06/2026

Phase II

C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…

DrugTilrekimig

Pfizer Inc.

Respiratory Tract Diseases

Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary

08/06/2026

Phase IV

PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)

2025-522049-23-00granulomatosis with polyangiitis and microscopic polyangiit…

DrugsPrednisone·Rituximab

Assistance Publique Hopitaux De Paris

Immune System Diseases

France

08/06/2026

Phase I/II

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small …

Novartis Pharma AG

Neoplasms

Spain, Italy, France, Denmark, Belgium

08/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

2025-523675-39-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Glaxosmithkline Research & Development Limited

Nutritional and Metabolic Diseases

Belgium, Greece, Poland, France, Spain, Bulgaria, Italy, Germany, Austria, Netherlands

08/06/2026

Phase III

OFA-VATS : Impact of opioid free anesthesia on postoperative quality of recovery and analgesia after video or robot assisted thoracic surgery

2025-524240-35-00indication for pulmonary resection surgery (segmentectomy o…

DrugsRemifentanil·Sufentanil·Dexmedetomidine

Centre Hospitalier Universitaire De Rennes

Anesthesia and Analgesia

France

05/06/2026

Phase III

ERPPAD - Efficacy in Relapse Prevention: Psilocybin in Alcohol use disorder with Depressive symptoms

2025-525069-65-00Alcohol use disorder, depressive symptoms

Centre Hospitalier Universitaire De Nimes

Mental Disorders

France

05/06/2026

Phase III

PACHA-02_Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of recurrence

2025-523913-27-00Participants with R0/R1 resected liver metastases from colo…

DrugsCalcium levofolinate·Folinic acid·Fluorouracil·Irinotecan

Unicancer

Neoplasms

France

05/06/2026

Phase IV

ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis

2025-521988-13-00Infection prophylaxis

DrugCefazolin

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

05/06/2026

Phase II

Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy

2025-523397-16-00Septic Coagulopathy

Les Hopitaux Universitaires De Strasbourg

Investigative Techniques

France

05/06/2026

Phase III

A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)

2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)

Eyebiotech Limited

Eye Diseases

Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia

05/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

2025-523912-35-00Narcolepsy Type 2

Alkermes Inc.

Nervous System Diseases

Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland

04/06/2026

Phase III

TicAgreLor versus placebo to prevent cerebral ISCHemia in anEuRysmal low grade SAH A double blinded randomised controlled study TALISCHER - SAH

2023-509795-42-00Aneurysmal subarachnoid hemorrhage

DrugTicagrelor

Centre Hospitalier Universitaire De Toulouse

Nervous System Diseases

France

04/06/2026

Phase I/II

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

2025-524232-20-00Patients with poor prognostic ovarian cancers based on the …

DrugsUbamatamab·Filgrastim·Paclitaxel·Bevacizumab

Asso De Recherche Cancers Gynecologiques

Neoplasms

France

04/06/2026

Phase I/II

A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.

2025-523590-42-00Locally Advanced or Metastatic Solid Tumors

Crescent Biopharma Inc.

Neoplasms

Spain, Ireland, Italy, France, Romania

02/06/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

2025-523911-13-00Narcolepsy Type 1

Alkermes Inc.

Nervous System Diseases

Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland

02/06/2026

Phase III

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

2025-523670-17-00Systemic lupus erythematosus

AstraZeneca AB

Immune System Diseases

Poland, Germany, Italy, France, Spain

02/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS

2025-522434-32-00Hemophilia A Without Inhibitors

F. Hoffmann-La Roche AG

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary

01/06/2026

Phase III

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

2022-502365-26-00Asthma

DrugSalbutamol

Novartis Pharma AG

Respiratory Tract Diseases

Poland, France, Slovakia, Spain, Hungary, Germany, Romania

01/06/2026

Phase III

A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A

2025-522435-33-00Hemophilia A

F. Hoffmann-La Roche AG

Hemic and Lymphatic Diseases

Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France

01/06/2026

Phase III

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

2025-524241-27-00Treatment-naїve mantle cell lymphoma (MCL)

DrugsOrelabrutinib·Bendamustine·Rituximab

Innocare Pharma Inc.

Neoplasms

Poland, France, Czechia, Spain, Romania

01/06/2026

Phase II

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

2024-516570-30-00Relapsed/refractory T-cell Acute Lymphoblastic Leukemia

DrugsAsparaginase Erwinia chrysanthemi·Tofacitinib·Everolimus·Azacitidine

Centre Hospitalier De Versailles

Hemic and Lymphatic Diseases

Germany, France, Czechia, Netherlands, Spain

29/05/2026

Phase II

Intravenous iron in the management of drug-resistant restless legs syndrome: a randomized controlled delayed-start trial. IRON-RLS

2026-525613-31-00Restless legs syndrome

DrugFerric Carboxymaltose

Centre Hospitalier Universitaire De Montpellier

Nervous System Diseases

France

29/05/2026

Phase IV

Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery: Impact on Postoperative Cardiovascular Outcomes – DISCO Study

2025-524395-30-00heart failure

DrugsMetformin·Dapagliflozin

Centre Hospitalier Universitaire De Toulouse

Cardiovascular Diseases

France

29/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive

2025-523555-66-00Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharma AG

Neoplasms

Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France

29/05/2026

Phase II

Pilot study comparing the efficacy of intra-articular glenohumeral injection combined with suprascapular nerve block versus intra-articular glenohumeral corticosteroid injection in adhesive capsulitis.

2026-525317-31-00Retractile Capsulitis

Centre Hospitalier Universitaire De Nantes

Musculoskeletal Diseases

France

29/05/2026

Phase II

A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis

2025-523400-72-00Cystic fibrosis

Vertex Pharmaceuticals Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark

29/05/2026

Phase II

Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)

2025-524378-40-00Locally advanced high‑risk stage III rectal adenocarcinoma …

DrugKortuc

Institut Gustave Roussy

Neoplasms

France

28/05/2026

Phase II

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303)

2025-523539-20-00Low Grade Upper Tract Urothelial Carcinoma

Tyra Biosciences Inc.

Neoplasms

Bulgaria, France, Spain

28/05/2026

Phase I/II

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma

2025-523005-15-00Non-Hodgkin Lymphoma

Merck Sharp & Dohme LLC

Neoplasms

Poland, Italy, France, Germany, Spain

28/05/2026

Phase II

Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.

2024-516796-33-00The medical condition studied in IMMUNO-BOS is Bronchioliti…

Hospital Foch

Respiratory Tract Diseases

France

27/05/2026

Phase I/II

A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES-SCLC

2025-523276-23-00Extensive stage small cell lung cancer

DrugsBendamustine·Tocilizumab·Fludarabine·Cyclophosphamide

Novartis Pharma AG

Neoplasms

Spain, France

27/05/2026

Phase II

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials

2025-523579-47-00moderate to severe rheumatoid arthritis (RA)

DrugAfimkibart

F. Hoffmann-La Roche AG

Immune System Phenomena

Italy, Spain, Germany, France, Denmark, Poland, Belgium

27/05/2026

Phase I/II

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

2025-523997-18-00Sarcoma

Glaxosmithkline Research & Development Limited

Neoplasms

France

27/05/2026

Phase III

A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease

2025-521590-13-00Moderately to Severely Active Crohn’s Disease

Janssen Cilag International

Immune System Diseases

Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary

27/05/2026

Phase II

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis

2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…

Maplight Therapeutics Inc.

Mental Disorders

Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary

27/05/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy

2025-522949-22-00Duchenne muscular dystrophy

Solid Biosciences Inc.

Musculoskeletal Diseases

Spain, Netherlands, France, Italy, Belgium, Germany

26/05/2026

Phase I/II

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

2025-522339-32-00Neoplasm malignant

DrugIfinatamab Deruxtecan

Merck Sharp & Dohme LLC

Neoplasms

France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia

26/05/2026

Phase II

POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug

2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)

DrugZoledronic Acid

Assistance Publique Hopitaux De Paris

Musculoskeletal Diseases

France

26/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

2025-524040-35-00Severe uncontrolled asthma

Generate Biomedicines Inc.

Respiratory Tract Diseases

Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia

26/05/2026

Phase II

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

2025-524181-26-00relapsed/refractory multiple myeloma

DrugCemsidomide

C4 Therapeutics Inc.

Hemic and Lymphatic Diseases

Italy, France, Spain, Poland

25/05/2026

Phase III

Comparison of iodinated contrast media injection protocols with reduced flow rates and volumes on image quality in diagnostic cerebral angiography for the evaluation of unruptured intracranial aneurysms: towards a standardization of practices (OPIAC)

2025-524884-18-01Intracranial aneurysms

Les Hopitaux Universitaires De Strasbourg

Nervous System Diseases

France

22/05/2026

Phase II

UNLOCK - EPIBREAST, a phase II study of prifetrastat (PF-07248144), a KAT6 inhibitor, plus fulvestrant for advanced HR+/HER2- breast cancer with biomarkers analysis

2025-521982-29-00Adult patients with advanced hormone receptor positive (HR+…

DrugsPrifetrastat·Fulvestrant

Unicancer

Neoplasms

France

22/05/2026

Phase III

ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy

2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland

22/05/2026

Phase I/II

A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours

2025-524620-22-00Neoplasms benign malignant and unspecified (incl. cysts and…

DrugsODM-212·Sotorasib·Ipilimumab·Nivolumab

Orion Corporation

Neoplasms

Finland, Denmark, Spain, France

22/05/2026

Phase II

A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).

2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

DrugPembrolizumab

Eikon Therapeutics Inc.

Neoplasms

Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland

21/05/2026

Phase II

An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

2025-524367-20-00Adult patients with primary mitochondrial disease

Pharming Technologies B.V.

Metabolism

Belgium, Germany, Czechia, Spain, Denmark, Italy, France

21/05/2026

Phase I

First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors

2025-524165-25-00Neoplasms

Glaxosmithkline Research & Development Limited

Neoplasms

Spain, Denmark, Finland, France

21/05/2026

Phase II

An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up

2025-523280-38-00Thyroid Eye Disease

Amgen Inc.

Eye Diseases

Spain, Poland, France, Italy, Greece

20/05/2026

Phase III

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib

2025-524078-40-00Chronic Spontaneous Urticaria

Novartis Pharma AG

Skin and Connective Tissue Diseases

Germany, Spain, France, Poland, Bulgaria, Czechia

20/05/2026

Phase III

A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa

2025-523259-72-00Hidradenitis Suppurativa (HS)

Novartis Pharma AG

Immune System Diseases

Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Denmark

20/05/2026

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping

2025-523087-20-00Duchenne muscular dystrophy

DrugAOC 1044

Avidity Biosciences Inc.

Musculoskeletal Diseases

Italy, Germany, France, Spain, Belgium, Poland, Netherlands

20/05/2026

Phase III

Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial

2025-524408-30-01Metastatic hormone-sensitive prostate cancer

DrugApalutamide

Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard

Neoplasms

Spain, Germany, France, Portugal, Italy

19/05/2026

Phase III

A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)

2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…

VarmX B.V.

Hemic and Lymphatic Diseases

Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania

19/05/2026

Phase II

PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases

2025-523425-17-00Proteinuric kidney diseases

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Nutritional and Metabolic Diseases

Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia

19/05/2026

Phase II

Beamion 44: A randomized, open-label, multi-center Phase IIa platform trial to evaluate the safety and tolerability of zongertinib plus Pt-doublet with or without pembrolizumab (and potential other combinations) in treatment-naïve patients with locally advanced/metastatic non-squamous NSCLC with activating HER2 mutations

2025-523567-38-00locally advanced or metastatic NSCLC

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Germany, France, Spain

19/05/2026

Phase II

An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer

AstraZeneca AB

Neoplasms

Italy, Spain, France, Netherlands

19/05/2026

Phase III

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer

DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin

Incyte Corp.

Neoplasms

Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy

19/05/2026

Phase III

Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).

2025-524475-23-00Neisseria gonorrhoeae Infections

DrugCeftriaxone

Assistance Publique Hopitaux De Paris

Bacterial Infections and Mycoses

France

18/05/2026

Phase I

A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease

2024-517310-15-00Parkinson's Disease

Mission Therapeutics Limited

Nervous System Diseases

Germany, Netherlands, France

18/05/2026

Phase III

EPISSOC : Randomized controlled trial comparing an Early Pleural Irrigation strategy with Saline to the Standard of Care for the management of complicated pleural infections

2025-524697-42-00Pleural infections

DrugsCefotaxime·Dornase Alfa·Clindamycin·Alteplase

Centre Hospitalier Universitaire Amiens Picardie

Respiratory Tract Diseases

France

18/05/2026

Phase II

INCREDIBLE: INCREmental DIalysis and diet for a Better Life Experience; Clinical relevance of an “add-on” Ketosteril supplementation on incremental haemodialysis period in incident haemodialysis patients. An exploratory randomized controlled trial

2025-524093-41-00Incremental Haemodialysis

Centre Hospitalier Le Mans

Nutritional and Metabolic Diseases

France

18/05/2026

Phase II

Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum SHORT-LGV

2025-524978-42-00Asymptomatic anal LGV infection

DrugDoxycycline

Centre Hospitalier Universitaire De Bordeaux

Bacterial Infections and Mycoses

France

18/05/2026

Phase I/II

mRNA Therapy to restore lymphatic flow in secondary lymphedema

2024-520149-22-00Lymphedema

Centre Hospitalier Universitaire De Toulouse

Hemic and Lymphatic Diseases

France

18/05/2026

Phase IV

Prognostic value of early assessment by ⁶⁸Ga-DOTATATE PET/CT for the treatment of well-differentiated grade 2 gastroenteropancreatic neuroendocrine tumors with ¹⁷⁷Lutetium-oxodotreotide.”

2025-524942-87-00Gastroenteropancreatic neuroendocrine tumors

Centre De Lutte Contre Le Cancer Eugene Marquis

Neoplasms

France

18/05/2026

Phase II

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

2024-518871-74-00Locally Advanced or Metastatic Solid Tumours that harbour M…

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, France, Denmark

18/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)

DrugOrelabrutinib

Zenas Biopharma (USA) LLC

Nervous System Diseases

Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary

18/05/2026

Phase II

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…

Novartis Pharma AG

Neoplasms

Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary

18/05/2026

Phase IV

A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.

2025-524289-56-00Asthma

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Germany, Romania, Italy, Bulgaria, Poland, Slovakia, Spain, France

18/05/2026

Phase III

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

2025-522007-18-00Relapsed or Refractory Multiple Myeloma

Janssen Cilag International

Neoplasms

Spain, Norway, Germany, Greece, France, Italy, Netherlands

18/05/2026

Phase III

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%

2025-523586-18-00Non-Small Cell Lung Cancer

DrugPembrolizumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia

15/05/2026

Phase I/II

A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

2026-525248-13-00Advanced Solid Tumors

Eikon Therapeutics Inc.

Neoplasms

France, Spain, Norway, Italy, Germany, Austria, Poland, Finland, Belgium, Denmark, Portugal

15/05/2026

Phase III

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

2025-523389-26-00Relapsed/refractory primary central nervous system lymphoma

DrugsTirabrutinib·Temozolomide·Rituximab

Deciphera Pharmaceuticals Inc.

Nervous System Diseases

Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary

14/05/2026

Phase III

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

2025-524810-28-00Acute Promyelocytic Leukemia

DrugArsenic Trioxide

Quetzal Therapeutics LLC

Neoplasms

Germany, Poland, Spain, Romania, Italy, France

13/05/2026

Phase II

Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy

2025-524317-88-00Multiple System Atrophy

Alterity Therapeutics Limited

Nervous System Diseases

France

13/05/2026

Phase I/II

Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myeloid Leukemia eligible to intensive chemotherapy - MIDOVEN

2024-517130-17-00FLT3-mutated Acute Myeloid Leukemia

DrugVenetoclax

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

13/05/2026

Phase III

A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.

2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…

DrugsObrixtamig·Tocilizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway

13/05/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Prurigo Nodularis

2025-523404-74-00Prurigo Nodularis

Innocare Pharma Inc.

Skin and Connective Tissue Diseases

Belgium, Poland, Germany, France, Austria

13/05/2026

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

2025-523106-32-00Obesity or Overweight and Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy

13/05/2026

Phase III

IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»

2025-521891-78-00Adult patients with stage IV non squamous non-small cell lu…

DrugsPemetrexed·Carboplatin·Pembrolizumab

Assistance Publique Hopitaux De Paris

Neoplasms

France

12/05/2026

Phase III

Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial

2025-525153-39-00Chronic thromboembolic pulmonary hypertension

Fondation Hopital Saint Joseph

Respiratory Tract Diseases

France

12/05/2026

Phase II

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

2026-525213-31-00Esophageal squamous cell carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Germany, France, Norway

12/05/2026

Phase III

DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.

2025-520565-51-00small cell lung cancer

DrugsObrixtamig·Tocilizumab·Atezolizumab·Carboplatin

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary

12/05/2026

Phase III

A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs

2025-522586-30-00Psoriatic Arthritis

DrugZasocitinib

Takeda Development Center Americas Inc.

Musculoskeletal Diseases

Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy

12/05/2026

Phase II

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

2025-523895-22-00Non-small cell lung cancer (NSCLC), Cervical cancer (CC), M…

DrugsBNT324·Pumitamig

Dualitybio Inc.

Neoplasms

Italy, Poland, France, Spain, Germany

12/05/2026

Phase III

MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease

2025-521331-36-00Patient with stabilized SSc-ILD (as defined by a decline of…

DrugRituximab

Assistance Publique Hopitaux De Paris

Skin and Connective Tissue Diseases

France

11/05/2026

Phase III

J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

2025-522255-25-00Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neop…

Eli Lilly & Co.

Neoplasms

Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany

11/05/2026

Phase III

A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies

2025-522983-33-00Chronic rhinosinusitis with nasal polyps

DrugItepekimab

Sanofi-Aventis Recherche & Developpement

Respiratory Tract Diseases

Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland

11/05/2026

Phase I

First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors

2025-521173-13-00Advanced Solid Tumors

Daiichi Sankyo Inc.

Neoplasms

France, Spain

08/05/2026

Phase I/II

A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies

2025-523399-22-00Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Car…

DrugsREGN10597·Cemiplimab

Regeneron Pharmaceuticals Inc.

Neoplasms

Italy, Spain, Germany, France

08/05/2026

Phase III

A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.

2025-522618-22-00Treatment of moderate to severe glabellar lines

Ipsen Innovation

Physical Phenomena

France, Germany

07/05/2026

Phase III

2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes

F. Hoffmann-La Roche AG

Nutritional and Metabolic Diseases

Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain

07/05/2026

Phase II

A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

2025-524843-11-00Non-Small Cell Lung Cancer

DrugsMycophenolate Mofetil·Infliximab·Ramucirumab·Rilvegostomig

AstraZeneca AB

Neoplasms

France, Italy, Spain

06/05/2026

Phase I

Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer

2025-522888-15-00Small Cell Lung Cancer

Amgen Inc.

Neoplasms

Spain, Germany, Poland, Belgium, France

05/05/2026

Phase III

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)

Dompe' Farmaceutici S.p.A.

Eye Diseases

Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France

05/05/2026

Phase III

A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia

2025-523811-12-00Achondroplasia

DrugVosoritide

Biomarin Pharmaceutical Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Poland, Italy, Romania, France, Norway

05/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

2025-523552-31-00Systemic Lupus Erythematosus

Janssen Cilag International

Immune System Diseases

Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland

05/05/2026

Phase III

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with obesity (AMAZE 1)

2024-520440-42-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Denmark, France, Germany, Belgium

04/05/2026

Phase II

A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration

2025-523704-77-00Geographic atrophy secondary to age-related macular degener…

Novartis Pharma AG

Eye Diseases

Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France

04/05/2026

Phase III

A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy

2024-519638-22-00IgA nephropathy

Novartis Pharma AG

Immune System Diseases

Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain

04/05/2026

Phase III

A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)

2024-516993-31-00Renal Cell Carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece

04/05/2026

Phase II

"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"

2025-524434-25-00gastric cancer

Drug[68Ga]Ga-FAPI-46

Centre Hospitalier Universitaire De Bordeaux

Neoplasms

France

30/04/2026

Phase II

Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE

2025-524511-36-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

30/04/2026

Phase III

A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors

2025-523750-14-00refractory hypotension in distributive shock

Paion Pharma GmbH

Cardiovascular Diseases

Italy, Germany, France, Spain

30/04/2026

Phase III

A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)

2025-523285-25-00Relapsed or Refractory Multiple Myeloma

DrugsAZD0120·Carfilzomib·Pomalidomide·Bortezomib

AstraZeneca AB

Neoplasms

Norway, Poland, Spain, Germany, France, Italy

30/04/2026

Phase III

A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression

2025-522872-10-00Depressive episodes associated with Bipolar disorder I or I…

Xenon Pharmaceuticals Inc.

Mental Disorders

Bulgaria, Germany, France, Spain

28/04/2026

Phase I

AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors

2025-524056-63-00microsatellite instability high/mismatch repair deficient (…

Amgen Inc.

Neoplasms

Spain, France, Belgium

28/04/2026

Phase III

An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.

2024-520218-23-00Pulmonary Arterial Hypertension

Inhibikase Therapeutics Inc.

Cardiovascular Diseases

Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania

28/04/2026

Phase III

CIRCULATE III - Tailoring the decision for adjuvant chemotherapy using circulating tumour DNA, in patients with stage III colorectal cancer

2025-521045-24-00Stage III colorectal cancer

Unicancer

Neoplasms

France, Sweden

28/04/2026

Phase III

A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long‑term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)

2025-524160-38-00Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dM…

Merck Sharp & Dohme LLC

Neoplasms

Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark

28/04/2026

Phase III

ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial

2025-520842-31-00Population of study participants Pregnant women with PPROM …

DrugsCeftriaxone·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Female Urogenital Diseases and Pregnancy Complications

France

28/04/2026

Phase II

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease

2025-521154-42-00Sickle Cell Disease

CSL Behring LLC

Hemic and Lymphatic Diseases

Belgium, Netherlands, France, Italy

28/04/2026

Phase II

Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)

2025-521967-11-00The study population includes adult ICU patients with a hos…

DrugNaCl

Assistance Publique Hopitaux De Paris

Mental Disorders

France

28/04/2026

Phase III

A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1

2025-522957-20-00Myotonic Dystrophy Type 1

Dyne Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, Italy, Denmark, Germany, Belgium, France

28/04/2026

Phase III

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)

2023-508047-40-00Ovarian cancer

Merck Sharp & Dohme LLC

Neoplasms

Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden

28/04/2026

Phase III

A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)

2023-504135-40-00Classical Homocystinuria

Travere Therapeutics Inc.

Nutritional and Metabolic Diseases

Belgium, Ireland, Spain, Italy, Germany, France, Portugal, Poland

27/04/2026

Phase II

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis

2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)

Chiesi Farmaceutici S.p.A.

Respiratory Tract Diseases

Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania

27/04/2026

Phase III

Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).

2025-523804-62-00Obesity

Novo Nordisk A/S

Nutritional and Metabolic Diseases

Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands

27/04/2026

Phase III

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)

2025-523495-23-00Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines Inc.

Digestive System Diseases

France, Spain, Italy, Germany

27/04/2026

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)

2024-519298-21-00Cancer-Associated Thrombosis (CAT).

DrugCenvacibart

Regeneron Pharmaceuticals Inc.

Hemic and Lymphatic Diseases

Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain

27/04/2026

Phase III

SEMAFORCRANIO : Multicenter, double-blind, parallel, randomized controlled trial of the efficacy of semaglutide in hypothalamic obesity secondary to craniopharyngioma in children aged 12 to 17 years

2024-511114-20-00Craniopharyngioma

DrugSemaglutide

Centre Hospitalier Universitaire D'Angers

Nervous System Diseases

France

27/04/2026

Phase II

Methylphenidate for Early Awakening in Coma (MEAWAKE)

2025-524937-19-00Coma due to acute brain injury

DrugMethylphenidate

Rigshospitalet

Nervous System Diseases

Austria, Denmark, Germany, France

27/04/2026

Phase I/II

A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…

DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine

Novartis Pharma AG

Neoplasms

Italy, Spain, Germany, Netherlands, France, Denmark, Czechia

27/04/2026

Phase II

Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM

2025-524602-15-00Neurology

Hospices Civils De Lyon

Nervous System Diseases

France

24/04/2026

Phase III

ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled trial

2025-524122-18-00Septic shock

DrugsHydrocortisone·Norepinephrine·Midazolam·Propofol

Hospices Civils De Lyon

Not possible to specify

France

24/04/2026

Phase I/II

A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies

2025-523774-16-00Advanced malignancies

DrugsPM54·Pembrolizumab

Pharma Mar S.A.

Neoplasms

Spain, France, Italy

24/04/2026

Phase II

A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de novo minimal change disease

2025-520641-69-00Kidney disease

DrugsTacrolimus·Prednisolone·Obinutuzumab·Prednisone

Medizinische Universitaet Innsbruck

Immune System Diseases

Germany, Austria, France

23/04/2026

Phase I/II

COLOMBE - A multicentre, single arm, phase 1/2 study, aiming to assess the safety and efficacy of nivolumab and imiquimod combination in vulvar squamous cell carcinoma patients

2025-524759-29-00Vulvar Squamous Cell Carcinoma (VSCC) patients

DrugsImiquimod·Nivolumab

Centre Leon Berard

Female Urogenital Diseases and Pregnancy Complications

France

22/04/2026

Phase I/II

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

2025-523602-33-00Advanced or unresectable Hepatocellular Carcinoma (HCC)

DrugIpilimumab

Bristol-Myers Squibb Services Unlimited Company

Neoplasms

Poland, Spain, Germany, France, Italy

22/04/2026

Phase I

Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis

2025-522904-26-00Systemic Lupus Erythematosus (SLE) With or Without Active L…

Genentech Inc.

Immune System Diseases

Italy, Spain, France, Germany

22/04/2026

Phase II

NoELA_No Endocrine therapy in small HR+ HER2- low relapse risk Luminal A early breast cancer, a single-arm de-escalation trial

2025-523683-20-00Postmenopausal patients with small (pT1a-b pN0) hormone rec…

DrugsTamoxifen·Exemestane·Anastrozole·Letrozole

Unicancer

Neoplasms

France

21/04/2026

Phase III

A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia

2025-524209-34-00Chemotherapy induced thrombocytopenia

Jiangsu Hengrui Pharmaceuticals Co. Ltd.

Not possible to specify

France, Romania, Poland, Spain, Bulgaria

21/04/2026

Phase III

A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension

2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardson…

Novartis Pharma AG

Nervous System Diseases

Netherlands, Germany, Spain, Italy, France, Belgium

21/04/2026

Phase I/II

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected …

Institut De Recherches Internationales Servier IRIS

Neoplasms

France, Spain, Denmark, Italy

21/04/2026

Phase III

KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial

2025-523149-80-00Adult patients admitted to the ICU and receiving unplanned …

Assistance Publique Hopitaux De Paris

Respiratory Tract Diseases

France

20/04/2026

Phase III

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia

2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia

BeOne Medicines I GmbH

Neoplasms

Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden

20/04/2026

Phase II

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)

2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…

CSL Behring LLC

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands

20/04/2026

Phase I/II

Double-blind, randomized, placebo-controlled, study to evaluate the safety and efficacy of HRX215 in participants after major hepatectomy, preceded by two open pilot parts in participants after minor and after major hepatectomy due to colon carcinoma metastases

2025-523630-59-00colon carcinoma metastases

HepaRegeniX GmbH

Neoplasms

France, Spain, Germany

20/04/2026

Phase I

A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced re…

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Neoplasms

Spain, France, Belgium, Germany

20/04/2026

Phase I

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myelo…

DrugPivekimab Sunirine

AbbVie Deutschland GmbH & Co. KG

Neoplasms

Spain, Hungary, Czechia, France, Italy, Belgium

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

2024-517337-41-00Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated N…

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Germany, Poland, Greece, France

20/04/2026

Phase III

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

2024-520014-22-00Locally advanced/metastatic urothelial carcinoma

Merck Sharp & Dohme LLC

Neoplasms

Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France

20/04/2026

Phase III

C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY

2025-523660-21-00severe to moderately severe hemophilia B (FIX:C ≤ 2%), hemo…

Pfizer Inc.

Hemic and Lymphatic Diseases

Italy, Germany, France, Spain, Sweden, Greece

20/04/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis

2025-524002-16-00Amyotrophic Lateral Sclerosis

Ferrer Internacional S.A., Prilenia Therapeutics B.V.

Nervous System Diseases

Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain

20/04/2026

Phase III

J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.

2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…

DrugsEnfortumab Vedotin·Pembrolizumab

Eli Lilly & Co.

Neoplasms

Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain

20/04/2026

Phase II

IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease

2025-522790-10-00Non Small Cell Lung Cancer, Interstitial Lung Disease

DrugsVinorelbine·Pemetrexed·Nivolumab·Gemcitabine

Intergroupe Francophone De Cancerologie Thoracique

Neoplasms

France

17/04/2026

Phase II

A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease

2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

DrugVancomycin

MaaT PHARMA

Digestive System Diseases

Netherlands, Italy, France, Spain

17/04/2026

Phase III

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)

2025-522748-42-00Ovarian cancer

DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel

Incyte Corp.

Neoplasms

Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium

17/04/2026

Phase III

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

2025-523717-29-00HFpEF or HFmrEF and obesity

Novo Nordisk A/S

Cardiovascular Diseases

Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France

17/04/2026

Phase III

A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions

2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)

Takeda Development Center Americas Inc.

Hemic and Lymphatic Diseases

France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands

17/04/2026

Phase II

METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0

2025-522655-26-00METAREM:Patients with advanced cancer, as defined as unrese…

Unicancer

Neoplasms

France

16/04/2026

Phase IV

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

2025-524573-16-00Crohn's disease

i-GETAID

Digestive System Diseases

France

16/04/2026

Phase I/II

An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors

2025-521911-38-00Advanced HR+/HER- breast cancer

DrugsLeuprorelin Acetate·Goserelin·Letrozole·Fulvestrant

Novartis Pharma AG

Neoplasms

Italy, Germany, France, Czechia, Denmark, Spain

16/04/2026

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects with Friedreich’s Ataxia

2025-521628-31-00Friedreich’s ataxia is the most common inherited ataxia in …

DrugNomlabofusp

Larimar Therapeutics Inc.

Nervous System Diseases

France

16/04/2026

Phase III

A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease

2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebr…

Guerbet, Bracco Imaging S.p.A.

Cardiovascular Diseases

Italy, France, Czechia, Hungary, Spain, Germany, Poland

15/04/2026

Phase I

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

2025-524136-19-00Selected Advanced or Metastatic Solid Tumors

BeOne Medicines AG

Neoplasms

Italy, France

15/04/2026

Phase III

A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome

2025-523157-34-00Rett syndrome

UCB Biosciences Inc.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Spain, Poland, France, Hungary, Belgium, Italy, Germany

15/04/2026

Phase I/II

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

2025-522318-21-00Neoplasms, Colorectal

Glaxosmithkline Research & Development Limited

Neoplasms

Italy, Denmark, Spain, Sweden, Netherlands, France

14/04/2026

Phase I

A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

2025-521000-22-00Patients with advanced malignancies

Novartis Pharma AG

Neoplasms

Spain, Italy, France

14/04/2026

Phase II

Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).

2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)

DrugCenegermin

Dompe' Farmaceutici S.p.A.

Nervous System Diseases

Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland

14/04/2026

Phase II

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer

DrugPegfilgrastim

Genmab A/S

Neoplasms

Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland

14/04/2026

Phase II

C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

2025-522965-31-00Atopic Dermatitis

Pfizer Inc.

Skin and Connective Tissue Diseases

Poland, Czechia, Germany, Bulgaria, France

14/04/2026

Phase III

PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma

2025-521571-30-00Young Adults and adults with R/R B-cell acute lymphoblastic…

DrugsImmunoglobulins·Levofloxacin·Azithromycin·Amoxicillin

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

13/04/2026

Phase II

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

2025-523117-28-00Relapsed or Refractory Multiple Myeloma

Glaxosmithkline Research & Development Limited

Neoplasms

France, Germany, Greece, Netherlands, Spain

13/04/2026

Phase I

Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA

2025-524725-41-00Acute Myeloblastic Leukemia

Centre Hospitalier Universitaire De Nantes

Not possible to specify

France

10/04/2026

Phase II

A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)

2025-520976-25-00Relapsed/refractory multiple myeloma

DrugMezigdomide

Centre Hospitalier Universitaire De Saint Etienne

Hemic and Lymphatic Diseases

France

09/04/2026

Phase I

A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

2025-521001-40-00Advanced Malignancies and Hepatic Impairment

Novartis Pharma AG

Neoplasms

Spain, France, Italy

09/04/2026

Phase II

Retinoic acid and sperm production in infertile men

2024-519644-33-00oligozoospermia

Les Hopitaux Universitaires De Strasbourg

Not possible to specify

France

09/04/2026

Phase II

A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.

2025-522867-13-00Non Small Cell Lung Cancer

Merus B.V.

Not possible to specify

Spain, Belgium, Netherlands, Poland, Italy, France

09/04/2026

Phase I/II

C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors

2025-523526-40-00Advanced Solid Tumors

DrugsSigvotatug vedotin·PF-08634404

Pfizer Inc.

Neoplasms

Italy, Spain, France, Germany

09/04/2026

Phase I/II

C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular …

DrugsPF-08634404·Ipilimumab

Pfizer Inc.

Neoplasms

Spain, Italy, Germany, France

09/04/2026

Phase III

Efficacy of intravenous dexamethasone in prolonging the duration of spinal anesthesia with chloroprocaine in knee arthroscopy.

2023-505247-39-00Knee arthroscopy

DrugDexamethasone

Centre Medico Chirurgical Ambroise Pare Hartmann

Anesthesia and Analgesia

France

08/04/2026

Phase II

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

2025-521090-14-00Patients with relapsed/refractory symptomatic multiple myel…

DrugsMezigdomide·Carfilzomib·Dexamethasone

Assistance Publique Hopitaux De Paris

Hemic and Lymphatic Diseases

France

08/04/2026

Phase III

FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial

2024-514964-24-00ulcerative colitis

DrugsFilgotinib·Ustekinumab·Vedolizumab·Infliximab

University Hospital Of Clermont-Ferrand

Digestive System Diseases

France

08/04/2026

Phase I

A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

2025-524157-13-00Chronic Hepatitis B

Precision Biosciences Inc.

Virus Diseases

Romania, France

08/04/2026

Phase II

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…

ETOP IBCSG Partners Foundation

Neoplasms

France, Greece, Spain, Italy

08/04/2026

Phase III

An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease

2025-522460-33-00Stargardt Disease

DrugTinlarebant

Belite Bio Inc.

Eye Diseases

Netherlands, France, Belgium

07/04/2026

Phase III

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

2025-523522-41-00Extensive-Stage Small Cell Lung Cancer

DrugsPF-08634404·Etoposide·Atezolizumab·Carboplatin

Pfizer Inc.

Neoplasms

France, Italy, Germany, Spain

07/04/2026

Phase III

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

2025-521108-23-00Chronic Obstructive Pulmonary Disease

Glaxosmithkline Research & Development Limited

Respiratory Tract Diseases

Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania

07/04/2026

Phase III

Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis

2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis

Alfasigma S.p.A.

Musculoskeletal Diseases

Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia

07/04/2026

Phase III

Evaluation of the efficacy and safety of bimekizumab (BZK) or adalimumab (ADA) in the treatment of anterior chest wall pain associated with active axial spondyloarthritis refractory to NSAIDs with hypothesis of superiority of bimekizumab. Randomized, open-label, in parallel arms, head to head trial (ThoracSPA)

2025-520632-42-00axial or predominantly axial SpA with or without psoriasis

DrugsBimekizumab·Adalimumab

Centre Hospitalier Universitaire Rouen

Musculoskeletal Diseases

France

03/04/2026

Phase III

Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, double-blind, placebo-controlled, phase 3 trial PEACH 2

2024-515663-59-00intracerebral haemorrhage

DrugLevetiracetam

Hospices Civils De Lyon

Nervous System Diseases

France

02/04/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

2025-522343-18-00Autosomal Dominant RYR1-Related Myopathy

Rycarma Therapeutics Inc.

Musculoskeletal Diseases

Netherlands, Spain, France, Germany

02/04/2026

Phase III

AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A Multicentre, Randomized Study

2023-509421-41-03Vaginal flora abnormalities, High risk preterm birth pregna…

DrugsAzithromycin·Metronidazole

Assistance Publique Hopitaux De Marseille

Bacterial Infections and Mycoses

France

01/04/2026

Phase III

Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).

2025-523239-21-00Juvenile idiopathic arthritis

Alfasigma S.p.A.

Immune System Diseases

France, Germany, Poland, Belgium, Hungary, Greece

01/04/2026

Phase II

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD328 in adult subjects with moderate to severe hidradenitis suppurativa

2025-521865-29-00moderate-to-severe hidradenitis suppurativa

Almirall S.A.

Skin and Connective Tissue Diseases

Bulgaria, Spain, France, Poland, Germany

01/04/2026

Phase IV

GLIFLOFASTER : EARLY GLIFLOZIN TREATMENT IN ELDERLY PATIENT HOSPITALIZED FOR DECOMPENSATED CHRONIC HEART FAILURE ADMITTED IN THE EMERGENCY ROOM - A FEASIBILITY STUDY

2025-521101-40-00CHRONIC DECOMPENSATED HEART FAILURE

Centre Hospitalier Regional Universitaire

Cardiovascular Diseases

France

31/03/2026

Phase I/II

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)

2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)

DrugsRamucirumab·Rilvegostomig

AstraZeneca AB

Neoplasms

Germany, Spain, France, Poland, Belgium, Netherlands, Italy

30/03/2026

Phase III

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer

AstraZeneca AB

Pathological Conditions, Signs and Symptoms

Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany

27/03/2026

Phase III

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

2024-519818-31-01Endometrial Cancer Advanced, Recurrent, Metastatic, or Prim…

DrugsDoxorubicin·Paclitaxel

Genmab A/S

Neoplasms

Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy

26/03/2026

Phase II

PNOC029_Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults

2024-511510-20-00craniopharyngioma

DrugTovorafenib

Prinses Maxima Centrum voor Kinderoncologie B.V.

Neoplasms

Netherlands, France, Germany

25/03/2026

Phase II

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

2025-523803-31-00Advanced non-small cell lung cancer (NSCLC)

Shanghai Henlius Biotech Inc.

Therapeutics

Italy, Romania, Poland, Spain, France

25/03/2026

Phase IV

Non-inferiority study of TOCILIZUMAB in dose-banding versus dose-weight in rheumatoid arthritis with low activity or clinical remission

2025-522319-41-00rheumatoid arthritis

DrugTocilizumab

Centre Hospitalier Universitaire De Nice

Musculoskeletal Diseases

France

24/03/2026

Phase II

MitOxyVit: Mitochondrial network modulation approach using hyperbaric oxygen (HBO) therapy and NNbUVB for treating vitiligo

2025-524709-34-00Vitiligo

Centre Hospitalier Universitaire De Nice

Skin and Connective Tissue Diseases

France

24/03/2026

Phase III

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction

2025-522475-28-00Pulmonary Hypertension (PH) with Heart Failure with preserv…

Tenax Therapeutics Inc.

Cardiovascular Diseases

France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain

24/03/2026

Phase III

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Pfizer Inc.

Neoplasms

France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany

24/03/2026

Phase I

A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.

2025-522932-15-00Systemic Lupus Erythematosus

Glaxosmithkline Research & Development Limited

Immune System Diseases

Germany, France, Italy, Spain, Poland

23/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)

2025-520902-37-00Non-small cell lung cancer stage IV

Merck Sharp & Dohme LLC

Neoplasms

Italy, Spain, Poland, France

23/03/2026

Phase III

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).

2025-523085-24-00Biliary Tract Cancer

AstraZeneca AB

Neoplasms

Germany, Poland, Italy, Belgium, France, Netherlands, Spain

23/03/2026

Phase III

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)

2025-522403-17-00Nummular Dermatitis

Almirall S.A.

Skin and Connective Tissue Diseases

Italy, Bulgaria, Spain, Germany, Poland, France

23/03/2026

Phase II

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation

2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativ…

F. Hoffmann-La Roche AG

Neoplasms

France, Italy, Poland, Germany, Spain

23/03/2026

Phase II

A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer

2025-524542-10-00Endometrial cancer

Acrivon Therapeutics Inc.

Neoplasms

Italy, Germany, Spain, France

23/03/2026

Phase III

C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER

2025-523521-18-00Metastatic Colorectal Cancer

DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin

Pfizer Inc.

Neoplasms

Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark

23/03/2026

Phase II

PAROCAINE : Evaluation of the Clinical Tolerance of an Intra-Parotid Injection of Bupivacaine Combined with Dexamethasone After Parotidectomy for a Benign Tumor – Prospective Single-Center Cohort Study

2025-524358-32-00Indication opératoire validée de parotidectomie partielle p…

Centre Hospitalier Universitaire De Nimes

Otorhinolaryngologic Diseases

France

19/03/2026

Phase II

A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies

2025-523234-66-00Well-Controlled Recurrent Pericarditis

Kiniksa Pharmaceuticals GmbH

Therapeutics

Spain, Greece, Germany, France, Italy, Poland

19/03/2026

Phase I

Phase 1 trial of valemetostat and darolutamide in mCRPC

2025-522512-16-00Metastatic Castration Resistant Prostate Cancer (mCRPC)

Daiichi Sankyo Inc.

Neoplasms

Ireland, Spain, France

18/03/2026

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults with Pulmonary Arterial Hypertension

2024-514754-79-00Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals Inc.

Cardiovascular Diseases

Latvia, Belgium, France, Poland, Germany, Spain, Czechia

18/03/2026

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency

2025-522051-26-00Acquired Angioedema due to C1 Inhibitor Deficiency

DrugDeucrictibant

Pharvaris Netherlands B.V.

Immune System Diseases

Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria

17/03/2026

Phase I/II

A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors

2025-524010-28-00Advanced Solid Tumor

Repertoire Immune Medicines Inc.

Neoplasms

Spain, Ireland, Portugal, France

17/03/2026

Phase I/II

A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors

2025-523742-27-00Advanced solid tumors

Medilink Therapeutics (Suzhou) Co. Ltd.

Neoplasms

Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany

17/03/2026

Phase III

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

2025-522191-86-00Focal segmental glomerulosclerosis

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.

Female Urogenital Diseases and Pregnancy Complications

Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France

17/03/2026

Phase I

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

2025-523686-15-00Advanced or Metastatic Solid Tumors

Olema Pharmaceuticals Inc.

Neoplasms

Ireland, Spain, France

17/03/2026

Phase III

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)

2025-522878-36-00Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics Inc.

Skin and Connective Tissue Diseases

Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland

16/03/2026

Phase IV

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)

2025-522118-21-00Axial Spondyloarthritis, Acute Anterior Uveitis

DrugUpadacitinib

Care Arthritis Ltd.

Eye Diseases

Spain, Poland, Netherlands, France, Bulgaria, Germany

13/03/2026

Phase III

“Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicentre Randomized Controlled Trial” THE IVT ALL IN TRIAL

2024-520414-21-00Adult patients with a LVOS with large core within 9 hours o…

DrugTenecteplase

Assistance Publique Hopitaux De Paris

Nervous System Diseases

France

12/03/2026

Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-europe/country/france

Query this register directly

GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,637 trial records at the last sync on 16 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 924 of those trials with a site in France.

How many recently authorised EU trials have a site in France?

924 of the 2,557 most recently authorised trials in this register list a site in France; 430 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (France), 924 trials
Phase	Trials	Share
Phase III	430	46.5%
Phase II	274	29.7%
Phase I	96	10.4%
Phase I/II	88	9.5%
Phase IV	36	3.9%

Most active sponsors

Lead sponsors with the most trials (France)
Lead sponsor	Trials
Assistance Publique Hopitaux De Paris	49
Novartis Pharma AG	35
AstraZeneca AB	29
Merck Sharp & Dohme LLC	28
Bristol-Myers Squibb Services Unlimited Company	26
Pfizer Inc.	24
Glaxosmithkline Research & Development Limited	23
Sanofi-Aventis Recherche & Developpement	23
F. Hoffmann-La Roche AG	22
Janssen Cilag International	19

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.